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1
Our research group has been dedicated to investigate the field of pelvic floor disorders 
(PFDs). The focus of our research has been on the validation and value of patient-reported 
outcome measures (PROMs), quality of life, and therapy outcomes in PFDs. This research 
line is continued and described in this thesis, and it is put in the context of developing a 
prediction model to optimize individualized care.
PELVIC FLOOR DISORDERS – URINARY INCONTINENCE 
The pelvic floor consists of muscles, bones and fascial components and is involved in both 
urinary and fecal continence, support of the pelvic organs, and sexual function. Malfunction 
of any of these components can disrupt the balance and cause PFDs. The most prevalent 
PFDs are urinary incontinence (UI), fecal incontinence and pelvic organ prolapse. These 
symptoms often present together.1, 2 Other PFDs involve pelvic pain syndromes and sexual 
dysfunction. The occurrence of PFDs has been associated with female gender, increased age, 
overweight or obesity, and pregnancy and (vaginal) deliveries.1, 3 PFDs can be considered a 
common healthcare problem. Although the symptoms are generally not life-threatening, 
they may have a significant negative impact on the quality of life.
UI is considered a storage symptom of the lower urinary tract, and is defined as the 
complaint of any involuntary leakage of urine.4 Two main types are distinguished: urge 
urinary incontinence (UUI), which is involuntary leakage accompanied by or immediately 
preceded by a sudden compelling desire to pass urine,4 and stress urinary incontinence 
(SUI), which occurs on exertion, effort, sneezing or coughing.4 These two types of UI often 
coexist.5 
UI is highly prevalent all over the world. It is estimated that worldwide about 200 million 
people experience UI.5 Depending on the definition used, UI is found in 1-39% of adult men6 
and 13-50% of adult women.2 The prevalence of UI in the Netherlands was recently studied 
and it was found that 36.8% of the Dutch adult population had experienced any UI during 
the past six months.7 Five percent of the Dutch population experiences UUI and about 5% 
experiences mixed incontinence, a combination of both UUI and SUI. The occurrence of UI 
has been associated with female gender, increased age, high BMI, comorbidity, pregnancy, 
labor, vaginal delivery, hysterectomy, prostatectomy and a positive family history for UI.6, 8 
UI showed to have major impact on a person’s quality of life and well-being.6, 9 Besides the 
impact on patients’ quality of life, the financial impact of UI on the healthcare system is 
tremendous. It was estimated that the healthcare costs for UI were in 2006 about 32 billion 
dollar per year in the United States.10
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PFDs and UI can be of neurological or non-neurological origin. PFDs of neurological origin 
can occur as a consequence of impaired neurological control of the pelvic floor and lower 
urinary tract caused by diseases such as spinal cord injury (SCI), multiple sclerosis (MS), and 
cerebrovascular accidents (CVA). The type of PFD depends on the location and the extent 
of the neurological lesion.11-13 For example, UUI is often associated with MS and CVA, SUI 
is often present in patients with conus-cauda lesions, and bladder emptying problems and 
high intravesical pressure (often leading to UI and upper urinary tract damage) are often 
present in patients with high level SCI. 
MANAGEMENT OF PELVIC FLOOR DISORDERS – URINARY INCONTINENCE
For the treatment of UI, different treatment modalities are available. Conservative, 
pharmacological and invasive treatments are typically first, second and third line treatments, 
respectively.14, 15 Conservative treatments include pelvic floor muscle training, education 
and lifestyle interventions, behavioral therapy and bladder training. Of these, pelvic floor 
muscle training (with or without bladder training) has been studied most extensively and is 
associated with higher success rates in the treatment of all types of UI than no treatment 
or other conservative treatment options.16, 17 Classically, when first line therapy has failed 
UUI is the domain of pharmacotherapy whereas SUI is the domain of surgical interventions. 
Pharmacological agents like muscarinic receptorantagonists17 and a selective beta-3-
adrenoceptor-agonist showed to be effective to treat UUI.18 In case of therapy-resistance 
for conservative and/or pharmacological treatments, minimal invasive therapeutical 
options are available to treat UUI, such as Botulinum toxin-A (BTX-A) injections and sacral 
neuromodulation.14, 15 Other surgical treatments such as a colposuspension, sling, artificial 
urinary sphincter (AUS), Adjustable Continence Therapy (ACT or ProACT), and urethral 
bulking agent showed to be effective to treat SUI.15
The treatment of neuro-urological (NU) patients with PFDs can be challenging due to damaged 
sensory pathways and the possibility of various dysfunctions presenting in parallel.19 It is 
important to recognize the neurological origin of a PFD when setting personalized treatment 
goals so that an essential treatment goal for NU patients, i.e. prevention of deterioration of 
the upper urinary tract, can be taken into account. Specific guidelines for the treatment of 
NU patients are developed.13 Clean intermittent catheterization is a conservative treatment 
option in patients with bladder emptying problems. Reconstructive surgery, such as the 
construction of an appendicovesicostomy with or without bladder augmentation and 
bladder neck surgery, is a treatment option to prevent deterioration of the upper urinary 
tract (in patients with high intravesical pressure), to regain continence and to solve bladder 
emptying problems. 
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OUTCOME MEASURES
Due to new developments such as the introduction of different (continence) devices, 
minimal invasive techniques, and new pharmaceutical agents, the research field of PFDs has 
expanded. Unfortunately, in most studies on non-neurogenic PFDs many different outcome 
parameters and definitions of cure were used.20, 21 Success in PFDs treatments to promote 
urinary continence can be defined, for example, as more than 50% reduction in UI episodes, 
as the patient using no or only one security incontinence pad per day, as satisfaction reported 
by the patient, or as a certain change in score on a PROM. Failure of a therapy could also 
be defined in different ways, for example, as the complication rate, as the re-intervention 
rate (after a surgical therapy), as less than 50% reduction in UI episodes or as dissatisfaction 
reported by the patient. 
Since several years the quality of life has become more and more important as an outcome 
measure in functional urology. It has been shown that the perceptions of a patient and its 
physician concerning the impact of PFDs on the quality of life often differ.22, 23 In order to 
objectivize this subjective parameter, PROMs have been introduced. PROMs are designed 
to make the subjective perception of the patient quantifiable and measurable for both 
patient and physician. PROMs can evaluate symptoms, bother or burden from symptoms, 
or (health-specific) quality of life. 
Various validated PROMs for the use in non-neurological PFDs are available in multiple 
languages to evaluate distress and bother from urinary complaints including UI (UDI-
6 and IIQ-7)24, sexual function (IIEF-525 and PISQ-1226), and bowel complaints and fecal 
incontinence (FIQL and FISI)27 and a combination of different PFD symptoms (PFDI-20 and 
PFIQ-7)28. In contrast, PROMs for the use in NU patients are not commonly available in 
different languages. Bother from PFDs experienced by NU patients might differ from bother 
experienced by non-neurological patients due to the differences in mobility, sensation and 
other additional symptoms caused by their neurological disease. Therefore it is important 
to have PROMs specifically designed for NU patients. Only the Actionable29, a screening 
questionnaire for neurogenic overactive bladder, is available in Dutch. The European 
Association of Urology guidelines recommend to implement PROMs, specifically concerning 
the quality of life, into clinical care for NU patients.13 In the Netherlands this is presently not 
possible due to the lack of Dutch translated and validated versions of the most important 
PROMs. 
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PREDICTION MODELS
As a consequence of the increasing number of treatment options in the management of PFDs, 
treatment decision making becomes more important. At present, the choice of treatment 
is often based on the experience and knowledge of the caregiver and on local treatment 
availability. This might not always result in the optimal treatment for the individual patient. 
While some patients respond to a certain type of treatment, others do not. At present, 
we are not able to identify patients who will and will not respond to a certain PFD therapy 
beforehand. 
Objective multivariate prediction models can be helpful. They showed to be effective to 
predict the risk of disease and treatment outcome in the individual patient. Prediction 
models have become popular tools in clinical practice in different areas of medicine and can 
be helpful in managing patients’ expectations, (shared) decision making, and optimization 
of personalized care.30 Diagnostic models predict the probability of the presence or absence 
of a current disease. These models are useful in the diagnostic setting, e.g., to support 
physicians in their decisions for referral of patients, or to perform further investigations 
or not. Prognostic prediction models can predict future disease risks or future (treatment) 
outcomes and can therefore facilitate treatment decision making.30, 31 
Although not widely used, prediction models in the field of PFDs are not completely new. An 
example is a prediction model developed by Jelovsek et al.32 that calculates the future risk 
to develop PFDs such as UI, pelvic organ prolapse and fecal incontinence for an individual 
patient after childbirth. It provides the opportunity to perform prevention therapies during 
pregnancy in high-risk patients, e.g., by deciding to perform a caesarian section instead of 
a vaginal delivery. Another example is a model that predicts the outcome of one specific 
pharmacological treatment for UUI (Fesoterodine) that is developed by Darekar et al.33 
A complete multivariate prediction model that predicts diagnosis and treatment outcome in 
the field of PFDs that can support (treatment) decision making, is not yet available. Such a 
prediction model for PFDs would be of great importance for the decision making in the first, 
the second and the third line of the health care system.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
GENERAL INTRODUCTION
15
1
THIS THESIS
The two fundamental research questions of this thesis are: 
1) Can we lay the foundations to construct a complete diagnostic and prognostic 
prediction model in PFDs in the future?
2) Can we construct the first part of this prediction model, a prognostic model that 
predicts the outcome of UUI treatment?
OUTLINE OF THIS THESIS
In part I of this thesis the focus is on outcome measures used in functional urology and more 
specifically in the NU patient group. In chapter 2 the use of different outcome parameters 
and definitions of cure after surgical treatment for SUI in NU patients is systematically 
researched. In chapters 3 and 4 the translation and validation process of the Dutch SF-
Qualiveen, a urinary specific quality of life PROM for NU patients, in MS and SCI patients, is 
described. 
The outcomes of different invasive therapies to manage PFDs are described in part II. Chapter 
5 focuses on the mechanism of action of a relatively new minimally invasive continence 
therapy named ProACT in men with UI after radical prostatectomy. The hypothesis that the 
ProACT induces changes of the static urethral pressure is studied. In chapter 6 we describe 
the outcomes, complications and re-interventions after appendicovesicostomy surgery in 
children. 
In part III, chapter 7, the development of a multivariate model for predicting the outcome 
of UUI treatment based on patient characteristics, patient history and investigations is 
described. 
In chapter 8 the findings of this thesis will be placed in the context of the present literature. 
Furthermore, the implications for research and clinical practice and future perspectives will 
be discussed. 
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PART I
OUTCOME MEASURES IN 
FUNCTIONAL UROLOGY

CHAPTER 2
Heterogeneity in reporting on urinary outcome 
and cure after surgical interventions for stress 
urinary incontinence in adult neuro-urological 
patients: A systematic review.
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ABSTRACT
Aims: To describe all outcome parameters and definitions of cure used to report on 
outcome of surgical interventions for stress urinary incontinence (SUI) in neuro-urological 
(NU) patients.
Methods: This systematic review was performed and reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The study 
protocol was registered and published (CRD42016033303; http://www.crd.york.ac.uk/
PROSPERO). Medline, Embase, Cochrane controlled trials databases and clinicaltrial.gov 
were systematically searched for relevant publications until February 2017. 
Results: A total of 3168 abstracts were screened. Seventeen studies reporting on SUI surgeries 
in NU patients were included. Sixteen different outcome parameters and nine definitions 
of cure were used. Six studies reported on objective outcome parameters mainly derived 
from urodynamic investigations. All studies reported on one or more subjective outcome 
parameters. Patient-reported pad use (reported during interview) was the most commonly 
used outcome parameter. Only three of 17 studies used standardized questionnaires (two 
on impact of incontinence and one on quality of life). Overall, a high risk of bias was found. 
Conclusions: We found a considerable heterogeneity in outcome parameters and definitions 
of cure used to report on outcome of surgical interventions for SUI in NU patients. The 
results of this systematic review may begin the dialogue to a future consensus on this topic. 
Standardization of outcome parameters and definitions of cure would enable researchers 
and clinicians to consistently compare outcomes of different studies and therapies. 
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INTRODUCTION
Patients with neurological disease may show various urological symptoms, depending on 
the type of disease and the neurological location of the lesion.1, 2 Both storage and voiding 
problems can considerably reduce patients quality of life.3 An impaired neurological 
control of the external sphincter may be the cause of stress urinary incontinence (SUI), 
defined as urinary incontinence that occurs on exertion, effort, sneezing or coughing.4 
This bothersome condition affects many neuro-urological (NU) patients, typically those 
with a meningomyelocele or a conus-cauda equina lesion.1 Owing to the fact that SUI 
in NU patients often occurs together with other urological dysfunction such as detrusor 
overactivity and reduced bladder compliance,1, 3 treatment of SUI in NU patients requires a 
specific approach. Moreover, NU patients may perceive bother from urinary incontinence 
differently compared to non-NU patients due to altered sensation and impaired mobility. 
Therefore, the outcome parameters and the definitions of success or cure used to report on 
outcome of surgical interventions for SUI in NU patients require specific attention.
To identify the most appropriate therapy, studies on the outcomes of the different therapies 
used to treat SUI in NU patients should ideally be reported in a standardized way. We 
performed a systematic review to describe all urinary parameters and definitions of success 
or cure used to report on outcome of surgical interventions for SUI in NU patients.
MATERIALS AND METHODS
Study registration
The study protocol was registered and published on PROSPERO (CRD42016033303) (http://
www.crd.york.ac.uk/PROSPERO). This systematic review was performed and reported 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement5 and Cochrane Handbook for Systematic Reviews of Interventions.6
Literature search 
The Medline, Embase, Cochrane controlled trials databases, and clinicaltrial.gov were 
systematically searched for all relevant publications until February 2017. The search strategy 
is available in Supplementary Material S1. Duplicates were removed. No date restrictions 
were applied. Non-English texts were excluded. Additionally, reference lists of relevant 
reviews were hand-searched for missed relevant articles. 
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Study selection
Our aim was to include all publications of original studies that used a predefined urinary 
outcome parameter or a definition of success or cure to report on outcome of surgical 
interventions for SUI in adult NU patients. Conference abstracts, reviews and case series 
with <10 NU patients were excluded. Reviews served only to check the references for 
eligible extra articles. Studies with both adult NU and non-NU patients or with both children 
and adult NU patients were included only if adult NU patients were separately reported on 
or if >90% of the study population were adult NU patients. 
Endnote (EndNote X7, Thomson Reuters, 1500 Spring Garden Street, Fourth Floor, 
Philadelphia, PA 19130, USA) was used to store identified abstracts and to sort the abstracts 
for inclusion and exclusion. Each title and abstract was reviewed for eligibility by two out of 
four reviewing authors (BB, JG, JS, SR) independently. Articles of which the abstract met the 
eligibility criteria were reviewed in full text. Full text selection was performed by two authors 
independently (JG, SR) using a standardized screening form. Discrepancy between the two 
authors was resolved by discussion or by consulting a third reviewer (BB). We reported on 
the literature search and study selection in a PRISMA flow diagram.5 
Outcomes
All urinary outcome parameters and definitions of cure or success used to report on outcome 
of surgical interventions for SUI in adult NU patients were summarized. Outcome parameters 
containing information from questionnaires and patient interviews were considered 
subjective outcome parameters. Outcome parameters were considered objective when 
derived from bladder diaries, pad tests, cough stress-tests or urodynamic investigations.
Data extraction and risk of bias assessment
Data on general study characteristics were retrieved by the first author and checked by 
JG. Two authors (SR and JG) independently extracted predefined data from the included 
publications using a standardized data extraction form. A risk of bias analysis for included 
non-randomized comparative studies was performed by using the Cochrane Risk of bias 
Assessment Tool 7 in combination with an assessment of the main confounders following 
the recommendations of the Cochrane handbook for non-randomized comparative studies.6 
A list of the main confounders was developed and a priori agreed on with clinical content 
experts (EAU Neuro-Urology guidelines panel). Identified confounders were age, gender, 
mixed versus stress incontinence, underlying NU pathology, perineal sensation, previous 
treatments for SUI, and previous pelvic surgeries. Confounders were determined for the 
studies during data extraction. The confounding bias was classified as ‘high’ if the confounder 
was not considered or described, was imbalanced between the groups or was unadjusted 
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2
during analysis. The risk of bias in non-comparative studies was determined by assessing the 
attrition bias (incomplete outcome data), the reporting bias (selective outcome reporting), 
and availability of an a priori protocol. External validity of these studies was reported by 
assessing whether participants were selected consecutively. This is a pragmatic approach 
based on methodological literature.8, 9 In addition, the main confounders were assessed for 
these studies. The risk of bias figure was computed in Review Manager (RevMan) version 5.3 
(Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). 
Subgroup analyses
Subgroup analyses were intended to be performed if there would be sufficient data. 
Predefined subgroups were men versus women, SUI versus mixed UI, underlying NU 
pathology, and no versus one/more former surgeries with potential effect on continence. 
RESULTS
Search results
Figure 1 shows the PRISMA flow diagram of the literature search and study selection. After 
screening of 3168 abstracts, 182 full texts were reviewed. Finally, 17 studies were included 
in this systematic review.10-26 
Characteristics of included studies 
The included studies were published between 1995 and 2017 and report the results of 
various SUI surgeries. Table 1 shows the descriptives of the included studies. Most studies 
had a retrospective single-arm study design. With one exception, all studies were single-
center studies. Twelve studies reported on NU patients only. A total of 452 NU patients 
were included in the studies. Most studies included mixed patient populations regarding 
underlying NU pathology, detrusor overactivity, mixed urinary incontinence and pure SUI, 
and patients with and without previous SUI and other pelvic surgeries. 
Results on outcome parameters
Table 2 shows the outcome parameters used per study. In total, 16 different outcome 
parameters were used in the 17 included studies. Furthermore categorization of the 
outcomes differed (e.g. patient-reported leakage/continence). Eleven studies had applied 
two or more outcome parameters. Six of the 17 studies reported on both an objective and 
a subjective outcome parameter. 
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Figure 1. PRISMA flow diagram of identified, excluded and included studies
NU, neuro-urological; SUI, stress urinary incontinence
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Objective outcome parameters
Six of 17 (35.3%) included studies reported on objective outcome parameters. Pad tests 
were not reported on. In one study patients used a bladder diary to report the number of 
urinary incontinence episodes per day. One study reported the results of a cough stress-test. 
Urodynamics was the most used investigation to measure an objective outcome parameter; 
that is, in five studies. Bladder capacity, compliance, maximum detrusor pressure, postvoid 
residual volume, leakage during videocystometrogram, and Valsalva leak point pressure 
were the objective outcome parameters that were derived from urodynamic investigations. 
Subjective outcome parameters
Patient-reported pad use (number of pads/24h or yes/no daily pad use reported during an 
interview) was the most utilized outcome parameter; used in eleven studies. Three studies 
applied standardized questionnaires. In seven studies patients reported on their urinary 
leakage status in a post-intervention interview. Two studies reported on patient satisfaction. 
Results on definition of success or cure
Table 3 provides an overview of the different definitions for cure or continence used. Fifteen 
of 17 studies reported on such a definition. In these 15 studies, nine different definitions 
were used. Only two of five studies that reported on cure, and used an objective and a 
subjective outcome parameter, used a combination of both outcomes to define cure. 
Subgroup analyses
It was not contributive or possible to perform subgroup analyses. First, the number of 
included studies was small; second, because most studies identified included mixed 
populations (gender, underlying NU pathology, SUI and mixed UI, former surgeries with 
potential effect on continence); and finally, subanalyses and information on predefined 
groups was often missing (Table 1).
Risk of bias assessment
Most of the included studies were assessed as having high or unclear risk of bias (Figure 2). 
In most retrospective studies, it was unclear if an a priori protocol was available and if there 
was selective outcome reporting. In one third of these studies, it was unclear if there were 
incomplete outcome data. Most studies included study participants consecutively. The two 
comparative studies had a high risk of bias for most assessed factors of the Cochrane Risk of 
bias Assessment Tool and the confounding factors. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
HETEROGENEITY IN REPORTING ON OUTCOME
33
2
Table 3. Used definitions of cure or continence to report on success of surgical interventions for SUI 
in adult NU patients.
Study Cure/
Continence
Definition used
Pannek et al.10
2017
Cure No pads or continence aids used
Phé et al.11
2017
Continence No pad use
Losco et al.12
2015 
Continent 
status = dry
If patient reported complete correction of SUI + no pads 
usage
El-Azab et al.13
2015
Cure Negative cough stress test + no leakage during physical 
examination
Costa et al.14
2013
Fully continent Patient-reported ‘fully continent’ 
Mehnert et al.15
2012
NR NR
Groen et al.16
2012
Cure Score of 10 on VAS (indicating no incontinence) or using 
no pads
Athanasopoulos et al.17
2012
Cure No leakage per urethra, 0 pads per day. 
Chartier Kastler et al.18
2010
Perfect 
continence
Dryness at least 4 hours between 2 catheterizations/
micturitions
Abdul-Rahman et al.19
2010
Cure Completely dry, no pads. 
Bersch et al.20
2009
Cure Subjective cure (no pads or continence aids) + objective 
cure (continence confirmed during urodynamic 
investigation)
Ramsay et al.21
2007
Socially 
continent
0 or 1 pads/day
Lai et al.22
2007
NR NR
Hamid et al.23
2003
Cure Cessation of using pads and dry on VCMG
Costa et al.24
2001
Continence Patient reporting no leakage and no use of pads
Bennett et al.25
1995
Cure Patient reporting no leakage
Nataluk et al.26
1995
Continent or 
total continence
Totally dry on postoperative interview
NR, not reported; NU, neuro-urological; SUI, stress urinary incontinence; VCMG, Videocystometrogram
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Figure 2. Risk of bias summary. 
NU, neuro-urological; SUI, stress urinary incontinence
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DISCUSSION
Principal findings
In this systematic review, we have presented all parameters and definitions of cure to report 
on the outcome of surgical interventions for SUI in adult NU patients. Sixteen different 
outcome parameters and nine different definitions of cure or continence were used. Most 
outcomes and definitions of cure were based on non-standardized patient self-assessments 
(of pad use per day or leakage/continence). A minority of studies made use of objective 
outcome parameters or validated questionnaires. To the best of our knowledge, this is the 
first systematic review on this topic in this specific patient group. It is evident that there is a 
considerable heterogeneity in the urinary outcome parameters and definitions of cure used 
to report on outcome of surgical interventions for SUI in adult NU patients. 
Findings in the context of the existing evidence
The heterogeneity of outcome reporting makes it more difficult to interpret and compare 
different studies and therapies. The Core Outcome Measures in Effectiveness Trials (COMET) 
initiative supports the development of standardized sets of outcomes in all fields of health 
research.27 In the field of urology such core outcome sets are available for prostate cancer 
and male sexual dysfunction, but not for UI. The International Continence Society (ICS) and 
the International Consultation on Incontinence (ICI) recommend using both objective and 
subjective outcome parameters in UI research.28, 29 Despite this, these organizations do not 
provide a definition of cure or make recommendations for the specific outcome parameters 
to be used. 
Specifically in the field of NU patients undergoing SUI surgery there is no consensus on 
outcome parameters. The ICS does not provide a recommendation on this topic for research 
in NU patients. The ICI recommends using changes in detrusor leak point pressure for 
research purposes in NU patients if appropriate.28 Nevertheless, this parameter was not 
used in any of the included studies in our systematic review. The EAU guidelines mention 
prevention of deterioration of the upper urinary tract and optimization of the quality of life 
as the most important urological treatment goals for NU patients.30 Therefore, we would 
expect urodynamic investigations and quality of life measures to be used more often in 
this patient group. NU patients may have altered sensation and impaired mobility and 
consequently perceive (UI) complaints different than to non-NU patients. Thus, measuring 
patients’ perception of UI complaints and their health-related quality of life (rather than 
quantifying symptoms) is important, especially in this patient group. Phé et al.31 and Castillo 
et al.32 reported in their reviews on the commonly used outcome parameters and definitions 
of cure or treatment success used after SUI surgery (not specifically on NU patients). Phé et 
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al.31 reviewed publications on all SUI surgeries from 1995 to 2014 and Castillo et al.32 focused 
on publications on female SUI from 2005 and 2006. In our systematic review, we found that 
five out of 17 (29.4%) included studies used outcome parameters derived from urodynamic 
investigations. Phé et al.31 and Castillo et al.32 found that urodynamic investigations were 
performed in 12 of 54 studies (22.2%) and in 37 of 92 studies (40.2%), respectively. Only two 
of the 17 (11.8%) studies in our review applied questionnaires on the impact of UI and only 
one study used quality-of-life assessments. The questionnaires administered were the UDI-
6, IIQ-7, visual analog scale for continence, and ICIQ male short form. These are validated 
questionnaires, but not specifically for NU patients. Although validated (disease-specific) 
quality of life questionnaires such as the (SF-)Qualiveen33, 34 have been introduced in the 
recent past, they have not always been available. In the review by Phé et al.31 validated 
questionnaires (including quality of life measures) were used in 55.6% and in the review by 
Castillo et al.32 validated questionnaires were used in 40.2% and quality of life measures were 
used in 60.9% of the studies. So contrary to our expectations, urodynamic investigations and 
quality of life measures were not used more often in our systematic review in NU patients. 
For retrospective studies, only available measures from clinical practice can be used. The 
high number of retrospective studies in our systematic review compared to Phé et al.31 and 
Castillo et al.32 could explain the different findings. On the other hand, one would expect 
quality of life measures and urodynamic investigations as standard of care in NU patients. 
Despite the ICS and ICI recommendations, in only six of 17 (35.3%) included studies in this 
systematic review both a subjective and an objective outcome parameter was used and only 
two of these studies used a combination of these parameters to define cure. Compared to 
the reviews of Phé et al.31 and Castillo et al.32 in non-neurological patients, where about half 
of the studies reported on both a subjective and an objective outcome, this number is low. 
The high number of retrospective studies could again be an explanation for this finding. 
Comparable to our results, in the reviews of Phé et al.31 and Castillo et al.32 a minority of 
studies used a combination of subjective and objective outcome parameters to define cure. 
Pad use reported by the patient during an interview was the most used outcome parameter 
in the studies included in our systematic review. Phé et al.31 reported on this outcome for 
some studies, but not structurally for all and Castillo et al.32 did not mention this outcome 
parameter in their review. In one included study17 of our review this outcome parameter 
was chosen because it would reflect the quality of life, referring to a publication by Stoffel 
et al.35 that found a correlation between patient-reported pad use and the impact of UI on 
quality of life. In other publications the reason for choosing this outcome parameter is not 
clear, but might be the ease of collecting this information (especially for retrospective series) 
for both patient and researcher; in addition it does not interfere in a patient’s “normal daily 
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voiding routine” (as a bladder diary might do). It is questionable if patient-reported pad 
use during an interview reflects the quantity of urine lost36 specifically for NU patients with 
altered sensation in whom the use of incontinence pads is often discouraged to prevent 
skin problems. Furthermore, it is unknown if patient-reported pad use is comparable to 
bladder diary reported pad use. As using this outcome parameter may be advantageous, we 
suggest to further investigate this outcome parameter on psychometric properties, such as 
test-retest reliability, correlation with bladder diary reported pad use, quantity of urine lost 
and quality of life. 
Implication for research and clinical practice 
Farag et al.37 reported on the success rates of surgical treatments for SUI in both adult and 
pediatric NU patients in a systematic review. Farag et al.37 compared the combined success 
rates of the included studies on urethral bulking agents to urethral sling procedures and 
artificial urinary sphincters. These studies however used variable definitions of success. A 
consistent comparison of the outcomes of therapy can only be made after standardization 
of outcome parameters and definitions of cure or success. We therefore recommend 
developing a core outcome set for use in UI research with NU patients. It is important that not 
only medical experts, but also patients and caregivers will be involved in the development 
of this outcome set, in order to include the various perspectives and also to increase 
the willingness to implement the outcome set. Until such a set has been developed, we 
recommend using an objective and a subjective outcome parameter and the combination 
of both to define cure. Because of the importance of the quality of life, specifically in NU 
patients, we recommend the use of a disease-specific quality of life questionnaire or a 
bother questionnaire validated for NU patients such as the (SF-)Qualiveen33, 34 as a subjective 
outcome parameter. Implementing such questionnaires in both research and clinical practice 
places a focus on optimization of the quality of life for these patients and makes it possible 
to compare outcomes of different studies. A clear recommendation for the use of a specific 
objective parameter is not feasible because there is insufficient scientific evidence on the 
psychometric properties of the different objective measures (bladder diaries, urodynamics 
and pad tests), specifically regarding NU patients.38 
Strengths and limitations
Performing this systematic review, we followed the recommended Cochrane6 and PRISMA 
guidelines5. Our study gives a clear overview of all used urinary parameters and definitions 
of success or cure to report on the outcome of surgical interventions for SUI in NU patients, 
and will hopefully begin the dialogue to a future consensus on this topic. Unfortunately, the 
included studies were primarily retrospective and of poor scientific quality. Furthermore, 
subgroup analyses were not possible due to the limited number of included studies. 
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CONCLUSIONS
This is the first systematic review that has evaluated the various urinary parameters and 
definitions of cure to report on outcome after surgery for SUI in adult NU patients. We found 
a considerable heterogeneity in used outcome parameters and definitions of cure. As it is 
difficult to interpret and compare the outcomes of different therapies as investigators use 
different reporting systems of outcomes and definitions of cure, the results of this study will 
hopefully begin the dialogue to a future consensus on this topic. 
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SUPPLEMENTARY MATERIAL S1. LITERATURE SEARCH STRATEGY. 
Database: Embase <1974 to 2017 March 09>, OVID Medline Epub Ahead of Print, In-Process 
& Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 
Present, EBM Reviews - Cochrane Central Register of Controlled Trials <February 2017>, 
EBM Reviews - Cochrane Database of Systematic Reviews <2005 to March 8, 2017>
Search Strategy:
--------------------------------------------------------------------------------
1 exp neurogenic bladder/ or exp Urinary Bladder, Neurogenic/ (16958)
2 (NLUTD or NLUTDs).tw,kw. (146)
3 ((neurogen* or neuropathic or neurologic* or neuro-urological) adj5 (bladder or lower 
urinary tract or LUTS or LUT or LUTD)).tw,kw. (13866)
4 or/1-3 (22201)
5 exp Urinary Incontinence/ or exp stress incontinence/ or exp mixed incontinence/ 
(98473)
6 ((urine or urinate or stress or mixed or urinary) adj5 incontinen*).tw,kw. (71029)
7 5 or 6 (114065)
8 (neurogen* or neuropathic or neurologic* or neuro-urological).tw,kw. (758285)
9 Nervous System Diseases/ or cerebrovascular disease/ or Cerebrovascular Disorders/ 
or cerebrovascular accident/ (421341)
10 spinal cord disease/ or Spinal Cord Diseases/ or Alzheimer Disease/ or 
meningomyelocele/ or multiple sclerosis/ (437831)
11 Parkinson disease/ or meningomyelocele/ or meningocele/ (202850)
12 diabetes mellitus/ or (diabetes or diabetic).tw,kw. (1425859)
13 ((spina* adj cord) or spina bifida or spina* dysraphism).tw,kw. (293144)
14 (multiple sclerosis or Parkinson* or Alzheimer* or myelitis or multiple systematic 
atroph*).tw,kw. (651005)
15 (dementia* or progressive supranuclear palsy or corticobasal degeneration or mental 
retardation or cerebral palsy).tw,kw. (329983)
16 ((cerebral vascular or nervous system or cerebrovascular) adj2 (disease* or disorder* 
or accident* or insult)).tw,kw. (96766)
17 (meningocele or meningomyelocele or myelomeningocele or myelodysplastic or 
meningitis).tw,kw. (155314)
18 (Stroke or strokes or poststroke or cerebral tumor* or brain tumor* or trauma*).tw,kw. 
(1292644)
19 (nerve tube defects or lumbar spine Degenerative disease* or disk prolapse or disk 
hernia).tw,kw. (1592)
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20 (lumbar canal stenosis or cauda syndrome or hydrocephalus or encephalitis).tw,kw. 
(127425)
21 (Iatrogenic pelvic nerve lesion* or peripheral neuropathy or tethered cord).tw,kw. 
(43083)
22 or/8-21 (4701030)
23 7 and 22 (20308)
24 4 or 23 (38391)
25 surgical technique/ or General Surgery/ or surgery/ (1085176)
26 (Surgery or surgical or operat* or resect*).tw,kw. (5172826)
27 exp collagen/ or exp dextranomer/ or exp bulking agent/ or exp dimeticone/ (400833)
28 exp hydroxyapatite/ or exp stem cell/ or exp Stem Cells/ or exp Hyaluronic Acid/ or exp 
Hydrogel/ or exp polyacrylamide gel/ (608868)
29 (bulking agent* or Zuidex or hyaluronic acid or dextranomer or Coaptite or 
Hydroxylapatite).tw,kw. (42811)
30 (Bulkamid or Polyacrylamide hydrogel or hydroxyapatite or Contigen).tw,kw. (46085)
31 (bovine collagen or Macroplastique or macroparticle* or Durasphere or zirconium 
oxide beads).tw,kw. (2401)
32 ((injection or injectable*) adj3 ureth*).tw,kw. (881)
33 exp transobturator tape/ or exp suburethral sling/ (9430)
34 (sling or slings or Miniarc or Needleless or Solyx or “Mesh”).tw,kw. (87284)
35 ((tape or tapes) adj4 (vaginal or transobturator or trans-obturator or biological or 
suburethral or retropubic or mid-urethral)).tw,kw. (5445)
36 (“TVT” or “TOT” or “TVT-O” or Monarc or BioArc or Uratape).tw,kw. (9979)
37 (Fascia* Lata or Rectus fascia* or Raz).tw,kw. (5253)
38 (Synthetic or Dacron or “PTFE-Gore-Tex” or Mersilene).tw,kw. (518282)
39 (suspend or Pelvicol or single incision or one incision or Ajust or Ophira).tw,kw. (11313)
40 (Argus or Saffyre or Remeex or InVance or “AdVance”).tw,kw. (143200)
41 (ACT or ProACT or ProACTTM or Pro-ACT or Pro-ACTTM or adjustable continence).
tw,kw. (503042)
42 (colposuspension or Burch or urethropexy or retropubic suspension).tw,kw. (4451)
43 ((artificial adj3 urinary adj3 sphincter) or AMS 800 or AMS800 or AMS792 or AMS 792).
tw,kw. (2341)
44 (((adjustable or extraurethral) adj3 balloon*) or (laparoscop* adj3 pelvic adj3 repair)).
tw,kw. (207)
45 exp colposuspension/ (1567)
46 or/25-45 (7361424)
47 24 and 46 (11332)
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48 (((prostat* or bladder) adj2 (cancer or carcinoma)) not (without or “not” or “non”)).ti. 
(210154)
49 47 not 48 (11277)
50 ((exp animals/ or exp animal/ or exp nonhuman/ or exp animal experiment/ or animal 
model/ or animal tissue/ or non human/) not (humans/ or human/)) or ((rats or mice 
or mouse or cats or dogs or animal* or cell lines) not (human* or men or women)).ti. 
(10792279)
51 ((child/ or Pediatrics/ or Adolescent/ or Infant/ or adolescence/ or newborn/) not 
(adult/ or aged/)) or ((baby or babies or child or children or pediatric* or paediatric* or 
peadiatric* or infant* or infancy or neonat* or newborn* or new born* or kid or kids 
or adolescen* or preschool or pre-school or toddler*) not (aged or adult* or elder* or 
senior or men or women)).ti. (4317342)
52 case report/ or case reports/ or case report.ti. (4140401)
53 Conference Abstract.pt. or Congresses as Topic/ (2602269)
54 note/ or editorial/ or letter/ or Comment/ or news/ (3872537)
55 or/50-54 (23357127)
56 49 not 55 (5572)
57 limit 56 to dd=20151230-20170309 use oemezd [Limit not valid in Ovid 
MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid 
MEDLINE(R) Publisher,CCTR,CDSR; records were retained] (125)
58 limit 56 to ed=20151230-20170309 use ppez [Limit not valid in Embase,CCTR,CDSR; 
records were retained] (119)
59 limit 56 to yr=”2016 -Current” use cctr (10)
60 limit 56 to yr=”2016 -Current” use coch (23)
61 (2016* or 2017*).ep. (951360)
62 56 and 61 (75)
63 57 or 58 or 59 or 60 or 62 (338)
64 remove duplicates from 63 (293)
65 limit 64 to english language [Limit not valid in CDSR; records were retained] (276)
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ABSTRACT
Aims: The SF-Qualiveen is a short questionnaire that measures the impact of urinary 
symptoms on the quality of life of patients with urological dysfunction due to neurological 
disorders. The aim of this study is to translate, culturally adapt and validate a Dutch version 
of the SF-Qualiveen for use in Multiple Sclerosis (MS) patients.
Methods: Cross-cultural adaptation of the original English SF-Qualiveen into Dutch was 
performed according to standardized guidelines. Adult MS patients with symptomatic urinary 
disorders who visited the Urology or Rehabilitation outpatient clinic of the Erasmus Medical 
Center completed the SF-Qualiveen and the Urinary Distress Inventory-6 (UDI-6), that 
evaluates bother caused by lower urinary tract symptoms and was used as a gold standard, at 
baseline and 1-2 weeks later. A control group recruited from the Otolaryngology outpatient 
clinic completed the questionnaires once. Reliability and validity were determined. 
Results: Fifty MS patients and 50 controls were included. SF-Qualiveen scores in patients 
were higher than in controls (on a scale of 0 – 4: 1.73 vs. 0.34; P < 0.001). Internal consistency 
(Cronbach’s alpha >0.8) and reproducibility (Intraclass correlation coefficients >0.8) were 
good for the total SF-Qualiveen. Content validity was adequate and a significant relationship 
between SF-Qualiveen and UDI-6 (r = 0.510-0.479, P < 0.001) confirmed good criterion 
validity. 
Conclusions: The Dutch SF-Qualiveen showed good measurement properties. We 
recommend its use to measure urinary-specific quality of life in MS patients in research and 
clinical practice in the Netherlands. 
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INTRODUCTION
Urological dysfunction is common in patients with multiple sclerosis (MS), with prevalence 
reported as high as 32% to 97%.1 This variance is at least partly related to the stage of 
the progression of the disease. While urinary storage symptoms (urgency, frequency and 
urinary incontinence) due to overactive contractions of the detrusor muscle often dominate 
in earlier disease, voiding problems (straining, intermittence, residual urine and retention) 
due to detrusor-sphincter dyssynergia often arise in addition to the storage symptoms in 
progressed disease.1 This bladder dysfunction is associated with an important worsening of 
the quality of life in patients with MS.2 
As differences have been noted between doctors’ and patients’ perceptions of the impact of 
a chronic disease like MS, there is a need for direct measurements of patients’ experiences 
to be informed about their perception of the impact of the disease on the quality of life.3 
The European Association of Urology (EAU) guidelines on Neuro-Urology highlight quality 
of life as an import aspect in the management of neuro-urological patients. The Qualiveen4 
and its more practical short form (SF-Qualiveen)5 are validated questionnaires for patients 
with MS evaluating the urinary-specific quality of life by assessing the impact of a broad 
range of bladder problems. The Qualiveen or SF-Qualiveen is recommended by the EAU for 
the assessment of health related quality of life in this patient group.6 
The Qualiveen contains 30 questions. It was developed and validated in French for both 
spinal cord injury and MS patients4, 7 and underwent successful cross-cultural adaptation 
into English,8 German,9 Italian,10 Portuguese,11 and Spanish.12 The SF-Qualiveen with eight 
questions proved to have good measurement properties in MS patients and is currently 
available in French and English.5 The aim of our study is to translate, culturally adapt and 
validate a Dutch version of the SF-Qualiveen in MS patients, so as to make the SF-Qualiveen 
suitable for MS patients in the Netherlands in both research and clinical practice. 
MATERIALS AND METHODS
Study design and population
This is a single-center, prospective (cohort) validation study. The local medical research ethics 
committee reviewed the research proposal with the number MEC-2014-534 and concluded 
that the rules as stated in the Medical Research Involving Human Subjects Act do not apply. 
Adult MS patients with urinary symptomatology who visited the Urology outpatient clinic of 
the Erasmus University Medical Center (Erasmus MC) Rotterdam, the Netherlands, between 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
CHAPTER 3
48
October 2015 and April 2016 were invited for the study. MS patients with similar symptoms 
who visited the Rehabilitation outpatient clinic of the Erasmus MC between February 2016 
and April 2016 were invited as well. Patients with Dutch language difficulties, cognitive 
impairment, active malignant tumors, acute attacks of MS (defined as an acute episode 
of focal neurological disturbance), symptomatic urinary tract infections, and patients who 
changed treatment within the test-retest period were excluded. Patients were asked to 
complete two questionnaires (SF-Qualiveen and UDI-6); during a hospital visit (baseline) 
and 1-2 weeks later at home. All patients provided written informed consent. Patient and 
disease characteristics were retrieved from the medical files. 
Adult patients who visited the Otolaryngology outpatient clinic between March and May 
2016 were invited for the study as well. We considered these patients a proper control group, 
since Otolaryngology pathology is often limited to the organ and has no relationship with 
bladder problems. This group completed the questionnaires only once. Exclusion criteria for 
this group were: neuro-urological dysfunction (patients reporting both bladder symptoms 
and MS or spinal cord injury), cognitive impairment and Dutch language difficulties. 
Questionnaires
The SF-Qualiveen5 is a validated short version of the Qualiveen-304 questionnaire and 
evaluates urinary-specific quality of life. The SF-Qualiveen consists of eight questions and 
reports on four domains of two questions each: bother with limitations, fears, feelings and 
frequency of limitations. Table 1 displays the items of the SF-Qualiveen. Responses are 
given on a 5-point Likert like scale, where a score of 0 indicates ”no impact” and 4 ”high 
impact”. The SF-Qualiveen total score is calculated as the mean of the eight responses and 
the domain scores are calculated as the mean score of the responses per domain.
The Dutch Urinary Distress Inventory (UDI-6) evaluates bother caused by lower urinary tract 
symptoms.13 It consists of six questions and reports on three domains: irritative, stress and 
obstructive/discomfort symptoms. Answers can be given on a 4-point Likert like scale. The 
questionnaire is validated, but not specifically for neuro-urological patients. 
Table 1. Items of the SF-Qualiveen
Domains: Questions:
Bother with 
limitations
1. In general, do your bladder problems complicate your life?
2. Are you bothered by the time spent passing urine or realizing catheterization?
Fears 3. Do you worry about your bladder problems worsening?
4. Do you worry about smelling of urine?
Feeling 5. Do you feel worried because of your bladder problems?
6. Do you feel embarrassed because of your bladder problems?
Frequency of 
limitations
7. Is your life regulated by your bladder problems?
8. Can you go out without planning anything in advance?
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Cross-cultural adaptation
The cross-cultural adaptation of the original English SF-Qualiveen into the Dutch language 
was performed according to standardized guidelines for linguistic validation.14 The 
forward-translation was performed by two professional native Dutch-speaking translators 
separately, followed by a consensus meeting of these two and the primary investigator (SR). 
The consensus version was backward translated by a native English speaking translator. 
During a consensus meeting with the Dutch translators, the English translator and the 
primary investigator (SR) a few minor adjustments were made. Two urologists (BB and JS) 
proof-read and agreed on this version of the Dutch SF-Qualiveen. It was then evaluated 
on content validity,15 i.e. pre-tested, in face-to-face interviews with patients during August 
and September 2015. We aimed to include at least 10 MS patients for the face-to-face 
interviews. These patients were first asked to complete the questionnaire. Thereafter, 
content and wording of the questions were discussed with the patients and suggestions for 
improvement were solicited. 
Validation – reliability
Internal consistency 
This is the intercorrelation of the questions of a questionnaire and demonstrates if the 
questions measure the same underlying concept. The correlation between the questions 
of the SF-Qualiveen for the total score and for the separate domains were measured by 
determination of the Cronbach’s alpha. If Cronbach’s alpha was between 0.7 and 0.95, 
internal consistency was considered good.15
Reproducibility 
The intraclass correlation coefficients (ICC) for agreement were calculated for the overall 
SF-Qualiveen score and for the four domains to test the test-retest reliability. A score of 0.7 
or higher was considered good.15
Limits of agreement 
The limits of agreement (LOA) were calculated as the mean change in scores of repeated 
measurements ± 1.96 x SD of the changes. Provided differences within the LOA could be 
interpreted as measurement error and would not be clinically important. 16
 
Validation – validity
Content validity 
During the cross-cultural adaptation process, content validity was assessed by patient 
interviews. 
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Construct validity: 
Predefined hypotheses about the relation of the SF-Qualiveen to other measures were 
tested: 
- “Patients with higher SF-Qualiveen scores (indicating higher impact on urinary-
related quality of life) will have higher scores on the UDI-6 (indicating more bother 
of urinary symptoms).” The association between the SF-Qualiveen and UDI-6 
scores will be assessed using the Pearson’s correlation coefficient in case of a linear 
association. 
- ”The SF-Qualiveen scores in the patient group will be higher than the reference 
group.” The Student’s t-test will be used to assess the differences between groups.
Criterion validity 
For the SF-Qualiveen no perfect gold standard exists. In the absence of a perfect gold 
standard the UDI-6 is used as a gold standard to determine criterion validity. The correlation 
of the SF-Qualiveen to the UDI-6 is determined by using the Pearson correlation coefficient 
in case of a linear association. 
Floor and ceiling effects 
If more than 15% of respondents achieved the highest or lowest possible score, floor or 
ceiling effects are presumed to be present. We calculated the percentages of patients with 
the highest or lowest possible score. 
Further statistical methods
We aimed at a sample size of 50 MS patients and 50 control persons based on guidelines 
for validation of questionnaires.15 SPSS version 21 was used to perform the statistical 
analyses in this study. Mean ± standard deviations were used to present descriptive results 
for continuous data and counts and percentages for discrete data. Differences between 
groups were tested with Chi-Square tests for categorical variables and with Student’s t-tests 
for continuous variables. P-values of less than 0.05 were considered to reflect statistical 
significance.
RESULTS
Fifty-six MS patients with symptomatic urinary disorders were initially included in the study. 
Patients signed informed consent and filled in the baseline questionnaire. Six patients were 
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excluded afterwards for the following reasons: four patients did not return the second 
questionnaire for unknown reasons, one refused to fill in the second questionnaire and one 
changed treatment within the test-retest period. Eventually the data of 50 MS patients could 
be used for analyses. The mean time between completing the first and second questionnaire 
was 15.7 ± 10.6 days. 
Fifty persons who visited the Otolaryngology outpatient clinic of the Erasmus MC between 
March and May 2016 completed the questionnaires once as a control group. Table 2 displays 
the characteristics of the included MS patients and controls. The MS patient group was 
significantly older (P = 0.013) and had more females (P = 0.002) than the control group. Most 
patients had relapsing-remitting MS (60%), were limited in walking (46%), voided without 
catheterization (72%) and experienced both storage and voiding urinary symptoms (70%). 
Table 2. Patient and clinical characteristics
Patients Controls P-value
Characteristics
n 50 50    
Age at examination 
(years)
50.3 ± 11.7 42.3 ± 14.2 0.013
Gender Male
Female
11 (22.0%)
39 (78.0%)
26 (52.0%) 
24 (48.0%)
0.002
MS characteristics
Duration of MS since 
diagnosis (years)
13.3 ± 9.0
MS course Relapsing-remitting
Primary progressive
Secondary progressive
Missing
30 (60.0%)
5 (10.0%)
11 (22.0%)
4 (8.0%)
Mobility Fully ambulatory
Limited walking
Wheelchair bound
Missing
16 (32.0%)
23 (46.0%)
10 (20.0%)
1 (2.0%)
Urinary symptoms
Duration of urinary 
symptoms (years)
7.6 ± 5.5
Urinary symptoms Storage
Voiding
Storage + voiding
7 (14.0%)
8 (16.0%)
35 (70.0%)
Manner of bladder 
emptying
(normal) voiding
Intermittent catheterization
Indwelling catheter
36 (72.0%)
10 (20.0%)
4 (8.0%)
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Validation – reliability
Internal consistency 
With Cronbach’s alpha’s of >0.8, the internal consistency for the total SF-Qualiveen 
can be considered good. (Table 3) With a Cronbach’s alpha of >0.7 the domains ”bother 
with limitations” and ”feeling” showed a good internal consistency as well. The domain 
”frequency of limitations” showed moderate internal consistency and the domain ”fears” 
showed weak internal consistency. 
Table 3. Internal consistency – Cronbach’s alpha (n = 50 MS patients)
Test Re-test
SF-Qualiveen total 0.84 0.85
SF-Qualiveen subscales:
       Bother with limitations 0.72 0.78
       Fears 0.26 0.40
       Feeling 0.77 0.75
       Frequency of limitations 0.43 0.66
Reproducibility 
The ICCs for agreement for the total SF-Qualiveen and the four domains were all higher than 
0.7, indicating good reproducibility (Table 4).
Table 4. Reproducibility of SF-Qualiveen
Test
(mean ± SD)
Re-test
(mean ± SD)
Mean change 
(mean ± SD) 
ICC LOA
SF-Qualiveen total score 1.73 ± 0.84 1.73 ± 0.84 0.00 ± 0.39 0.90 -0.76 to 0.76
Bother with limitations 1.67 ± 1.10 1.70 ± 1.06 0.03 ± 0.61 0.84 -1.17 to 1.23
Fears 1.59 ± 0.98 1.58 ± 0.96 -0.01 ± 0.53 0.85 -1.05 to 1.03
Feeling 1.56 ± 1.09 1.50 ± 1.09 -0.06 ± 0.73 0.78 -1.50 to 1.38
Frequency of limitations 2.09 ± 0.95 2.13 ± 1.02 0.00 ± 0.39 0.72 -0.76 to 0.76
SD, standard deviation; ICC, intraclass correlation coefficient; LOA, limits of agreement
Limits of agreement 
The LOA ranges of the total SF-Qualiveen and the domains are presented in Table 4. A change 
of less than 0.76 in the total SF-Qualiveen score could be interpreted as measurement error. 
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Validation – validity
Content validity 
This was evaluated in face-to-face interviews with 11 MS patients and 12 other neuro-
urological patients. The importance of all questions, to assess the broad range of bladder 
problems patients experience, was confirmed by the majority of patients. The Dutch-
version questionnaire was found generally accessible, clear, easy to understand, and fast to 
complete and it was not necessary to make adjustments.
Construct validity 
Both predefined hypotheses about the relation of the SF-Qualiveen score to other measures 
were confirmed:
- We found a significant linear correlation between the total score of SF-Qualiveen 
and total score of UDI-6 in the patient group (T0: r = 0.510 and P < 0.001; T1: r 
= 0.479 and P < 0.001). This confirmed the hypothesis “patients with higher SF-
Qualiveen scores have higher UDI-6 scores”.
- The mean of the total score of the SF-Qualiveen differed between patient and the 
control group (1.73 vs. 0.34; P < 0.001). The hypothesis ”SF-Qualiveen scores in the 
patient group are higher than in the control group” is hereby confirmed. 
Criterion validity 
A significant relationship was found between the UDI-6 total score, and the SF-Qualiveen 
total score in both MS patient group (T0: r = 0.510 and P < 0.001; T1: r = 0.479 and P < 0.001) 
and the control group (r = 0.632 and P < 0.001).
Floor and ceiling effects 
In the patient group no floor or ceiling effects were found in total or domain scores. Two 
percent of patients had the lowest possible total score and no patients had the highest 
possible score. Four to ten percent of the patients reported the lowest possible scores for 
the separate domains. Zero to four percent of the patients reported the highest possible 
scores for the separate domains.
In the control group, floor effects were found in all domains and in the total score. (domains: 
58-86% and total score: 50%). No ceiling effects were found in the control group. 
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DISCUSSION
We translated the SF-Qualiveen into Dutch, and culturally adapted and validated it for use 
in MS patients. The measurement properties demonstrated the Dutch version of the SF-
Qualiveen to be valid, reliable and consistent. This enables the use of the SF-Qualiveen for 
future research and clinical practice in the Netherlands. 
For chronic diseases like MS, quality of life is an important aspect of healthcare. The urinary 
symptoms that are often described in patients with MS can diminish the quality of life.2 This 
study makes it possible for Dutch-speaking MS patients to directly measure the impact of 
urinary symptoms on the quality of life with the SF-Qualiveen. We chose to translate and 
validate the short form because this is more practical, easier to implement into research 
and clinical practice, and causes less patient burden to complete. In validation studies of 
the Qualiveen the length of the questionnaire has been mentioned as a limitation.11, 12 The 
Dutch SF-Qualiveen can be a valuable addition to diagnostics, so as the EAU guidelines 
recommends its use.6 
The Cronbach’s alpha of >0.8 indicates good internal consistency for the entire SF-Qualiveen 
questionnaire. For the development of the SF-Qualiveen Bonniaud et al.5 selected two 
questions per domain of the Qualiveen-30, based on the most responsive items to represent 
that domain. The authors did not address the internal consistency of the SF-Qualiveen, neither 
for the total score, nor for the domain scores. The internal consistency of a questionnaire is 
dependent upon the number of items in a scale.15 In a short questionnaire like the 8-item 
SF-Qualiveen categorization into 4 domains might therefore be questioned. In our study, 
the domains ”bother with limitations” and ”feeling” showed good internal consistency 
and the domain ”frequency of limitations” showed moderate internal consistency. The 
domain ”fears” showed weak internal consistency. Although its two questions (see Table 
1) are both important (as was confirmed during cross-cultural adaptation), the answers to 
these questions do not necessarily have to be associated. It is doubtful if the two questions 
measure the same underlying construct of ”fears”. A potential explanation for the moderate 
internal consistency of the questions within the domain ”frequency of limitations” (Table 
1) is that patients’ answers to the last question might not be exclusively related to their 
bladder problems. The question arising from our study results on the internal consistency of 
the separate domains and that each consists of only a small number of questions, is whether 
the domains of the SF-Qualiveen can still be considered as actual domains. Therefore, we 
investigated this issue by performing a factor analysis of the eight questions of the SF-
Qualiveen. This resulted in the identification of two components within the questionnaire. 
The first component is represented by the first seven questions and the second component 
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by question 8. This indicates that the four Qualiveen domains can no longer be identified 
in the SF-Qualiveen and that question 8 might assess a different construct than the other 
questions. This reasoning is confirmed by the Cronbach’s alpha rising from 0.835 to 0.855 
at baseline and from 0.851 to 0.871 at re-test when excluding question 8 from the analysis. 
Therefore, exclusion of question 8 from the questionnaire can be considered. In view of 
the good internal consistency of the total SF-Qualiveen, the lack of identification of four 
domains in the SF-Qualiveen, the patients agreement on the importance of all 8 questions 
of the questionnaire (content validity), and to support consistent (international) usage of 
the SF-Qualiveen we recommend to use the entire SF-Qualiveen questionnaire and not the 
separate domains. 
The ICCs showed a good reproducibility of the Dutch SF-Qualiveen. These ICCs are lower 
than reported in the original Qualiveen-30 questionnaire,4 but are comparable to those 
found in the French and English validation study of the SF-Qualiveen.5 The lower ICCs for the 
SF-Qualiveen are probably to the result of the shortening. We believe that the advantages 
of the short SF-Qualiveen (more practical, less patient burden and easier to implement into 
practice) outweigh this minor disadvantage. 
The Dutch SF-Qualiveen showed good validity. Predefined hypotheses to test construct 
validity could be confirmed. Patients’ scores on the SF-Qualiveen were significantly higher 
than those of controls, which demonstrates good discriminative ability of the SF-Qualiveen. 
Furthermore, a correlation was found between the UDI-6 as a gold standard and the SF-
Qualiveen. This confirmed good criterion validity. In the patient group no floor or ceiling 
effects were found. As expected, a floor-effect was found in the control group (no urological 
patients). 
One of the strengths of our study is that we followed all proposed quality criteria for the 
validation of a questionnaire of Terwee et al.15 Furthermore, we included a very homogeneous 
study population of only MS patients. Therefore we conclude that the SF-Qualiveen can 
be used to measure the urinary-specific quality of life for MS patients with symptomatic 
functional urologic disorders. Further research is needed to validate the questionnaire for 
other neurological diseases such as spinal cord injury. 
A limitation of this study is that we were no yet able to measure the responsiveness of 
the SF-Qualiveen. Another limitation is that the exact response rate cannot be established. 
We aimed at including all consecutive eligible patients. Study inclusions were performed by 
selected urologists and a rehabilitation specialist specialized in the treatment of MS patients. 
We were not able to establish whether indeed all eligible patients were approached by these 
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physicians and how many patients declined to participate. We could also have missed a small 
number of eligible patients who visited other (non-specifically MS specialized) urologists 
or rehabilitation specialists at our hospital during the inclusion period. Furthermore, there 
was no perfect gold standard questionnaire available. A perfect gold standard would be 
a questionnaire that is available in Dutch, commonly used, measures the urinary-specific 
quality of life and is validated in neuro-urological patients. In the absence of a perfect gold 
standard we chose the UDI-6, a commonly used questionnaire, which evaluates bother by 
lower urinary tract symptoms to function as the gold standard. Finally, due to the single-
center design of the study in a referral center, the generalizability of the questionnaire is 
questionable. On the other hand, the SF-Qualiveen showed good measurement properties 
in the original validation multicenter study.⁵
CONCLUSIONS
In conclusion, the Dutch version of the SF-Qualiveen showed good measurement properties. 
We recommend using the entire Dutch version of the short and practical SF-Qualiveen 
to measure urinary-specific quality of life experienced by MS patients in both research 
and clinical practice in the Netherlands. SF-Qualiveen outcomes can support healthcare 
professionals in treatment decision making to optimize patients’ quality of life. 
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ABSTRACT
Background: Optimizing the patients’ quality of life is one of the main goals in the urological 
management of spinal cord injury (SCI) patients. In this study we validated the Dutch SF-
Qualiveen, a short questionnaire that measures the urinary-specific quality of life, in SCI 
patients. No such measure is yet available for this patient group. 
Methods: In 2015-2016 SCI patients with urinary symptomatology who visited the 
outpatient clinics of Urology at the Erasmus Medical Centre and Rehabilitation at Rijndam 
Revalidation completed the SF-Qualiveen and UDI-6 during the visit and 1-2 weeks later. 
The UDI-6, a urinary tract symptom inventory, served as gold standard. Controls, recruited 
from the Otolaryngology outpatient clinic, completed the questionnaires once. Content-, 
construct-, and criterion validity and reliability (internal consistency and reproducibility) of 
the SF-Qualiveen were determined. 
Results: 57 SCI patients and 50 controls were included. 12 SCI patients asserted that the SF-
Qualiveen covered their bladder problems (good content validity). Patients’ SF-Qualiveen 
scores being positively associated with severity of urinary symptoms and patients’ scores 
being higher than those of controls indicated good construct validity. The positive association 
that was found between SF-Qualiveen and UDI-6 in patients (r = 0.66-0.67, P < 0.001) 
and controls (r = 0.63, P < 0.001) confirmed good criterion validity. Internal consistency 
(Cronbach’s alpha 0.89–0.92) and reproducibility (intraclass correlation coefficient 0.94) of 
the SF-Qualiveen were good. 
Conclusions: The Dutch SF-Qualiveen is a valid and reliable tool to measure the urinary-
specific quality of life in SCI patients. 
Trial registration: No trial registration (no clinical trial – no health-related intervention)
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BACKGROUND
Spinal cord injury (SCI) causes urological dysfunction in 70 - 84% of patients.1 The type 
of detrusor and/or sphincter dysfunction depends on the localization of the SCI and the 
damage to the spinal cord. Clinical presentation can vary from urinary incontinence to 
inability to empty the bladder.2 
More than two thirds of SCI patients in the Netherlands reported bladder regulation problems 
as one of their most frequent health problems.3 Bladder problems were perceived as a major 
secondary impairment and as having the greatest impact on social life.3 Bladder problems 
in patients with SCI were found to be associated with a lower quality of life.4 Optimizing the 
quality of life is considered one of the most important aspects in the urological management 
of patients with neuro-urological dysfunction due to SCI.5 
Currently, there is no validated measure available in the Netherlands to evaluate the 
urinary-specific quality of life in SCI patients. The Qualiveen-306 and its short version, the 
SF-Qualiveen,7 are measures that evaluate urinary-specific quality of life in patients with 
neurological disorders. The Qualiveen-30 has been validated in both multiple sclerosis (MS) 
and SCI patients,6, 8 but is not available in Dutch. Based on data of MS patients only, the 
eight most responsive items of the Qualiveen-30 were used to create the SF-Qualiveen.7 
The SF-Qualiveen has been validated in English7, French7 and Dutch9 for MS patients, but 
not yet for SCI patients. Although the neuro-urological dysfunction in MS and SCI patients is 
similar in some aspects, its clinical presentation and the influence on the quality of life might 
differ due to dissimilarities between the two diseases (e.g. the onset of disease is acute in 
SCI vs. progressive in MS; SCI often entails a total loss of sensation of the lower body, while 
MS entails an altered sensibility, but often no total loss of sensibility). For this reason, it is 
essential to evaluate the validity and reliability of the SF-Qualiveen in SCI patients before its 
use can be recommended as a measurement tool in the management of Dutch SCI patients 
to optimize their quality of life.
METHODS
Design and subjects
The research protocol (MEC-2014-534) was reviewed by the local medical research ethics 
committee, which concluded that the rules as stated in the Dutch Medical Research Involving 
Human Subjects Act did not apply to this study. The study was conducted at the Urology 
outpatient clinic of the Erasmus University Medical Center (Erasmus MC), Rotterdam, 
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the Netherlands and at the Rehabilitation outpatient clinic at Rijndam Rehabilitation, 
Rotterdam, the Netherlands. In August and September 2015 face-to-face interviews were 
conducted with SCI patients with urinary symptomatology to assess content-validity of the 
Dutch translated version of the SF-Qualiveen. Between late September 2015 and May 2016 
adult patients with SCI and urinary symptomatology were included. We intended to invite 
all eligible consecutive patients who visited the outpatients clinics to participate. Exclusion 
criteria were cognitive impairment, Dutch language difficulties, recent malignant tumors, 
symptomatic urinary tract infections, and (foreseen) change of (bladder-specific) treatment 
within the test-retest period. After having provided written informed consent, participants 
completed the SF-Qualiveen and the Urinary Distress Inventory-6 (UDI-6) at the outpatient 
clinic (test) and 1 to 2 weeks later at home (re-test). Clinical characteristics of included 
patients were retrieved from their medical charts. 
We used earlier collected data of a control group, that was recruited at the Otolaryngology 
outpatient clinic in 2016.9 Exclusion criteria for this group were cognitive impairment, Dutch 
language difficulties and neuro-urological dysfunction. The control patients had provided 
written informed consent and completed the measures once. 
Measures
The SF-Qualiveen is a measure that evaluates the urinary-specific quality of life in neuro-
urological patients. Table 1 shows the eight questions of the questionnaire. Each item is 
scored on an ordinal Likert scale ranging from 0 (no impact) to 4 (high impact). The total 
score is the mean of the eight separate scores7. The SF-Qualiveen consists of four domains, 
each containing two questions: bother with limitations (question 1 and 2), fears (question 3 
and 4), feelings (question 5 and 6) and frequency of limitations (question 7 and 8). 
Table 1. Questions of the SF-Qualiveen
1. In general, do your bladder problems complicate your life?
2. Are you bothered by the time spent passing urine or realizing catheterization?
3. Do you worry about your bladder problems worsening?
4. Do you worry about smelling of urine?
5. Do you feel worried because of your bladder problems?
6. Do you feel embarrassed because of your bladder problems?
7. Is your life regulated by your bladder problems?
8. Can you go out without planning anything in advance?
The Dutch UDI-6 is a validated Dutch measure,10 but has not been specifically validated in 
a neuro-urological patient group. The questionnaire (six questions) assesses the severity 
of urinary tract symptoms. It consists of three domains: irritative, stress and obstructive/
discomfort urinary symptoms.11 We chose this measure as a gold standard in the absence of 
a perfect gold standard for this patient group. 
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Validation process
The cross-cultural adaptation of the SF-Qualiveen into Dutch by our group was previously 
described.9 In short; two forward-translations of the SF-Qualiveen from English to Dutch, 
and one backward translation were followed by consensus meetings between translators 
and clinicians. Standardized guidelines for linguistic validation were followed.12 Content 
validity was assessed by face-to-face interviews with SCI and MS patients.13 The goal of 
these interviews was to confirm that the translated version of the SF-Qualiveen used clear 
wording and that it was a complete measure. 
In the current study, predefined hypotheses on construct validity were assessed: 
1. We hypothesized that SF-Qualiveen scores of patients would be positively 
associated with the severity of urinary symptoms (UDI-6 domains irritative, stress 
and obstructive/discomfort urinary symptoms and total score). 
2. We hypothesized that scores of the SF-Qualiveen in the patient group would be 
higher than scores in the control group.
Criterion validity was determined by assessing the relationship between the SF-Qualiveen 
and the UDI-6 as a gold standard. Floor and ceiling effects were presumed to be present if 
more than 15% of respondents achieved the highest or lowest possible score. Therefore, 
percentages of respondents with the highest and lowest possible score were calculated. A 
floor effect was to be expected in the control group. 
The internal consistency of the SF-Qualiveen questions, i.e. whether the questions measure 
the same underlying construct, was determined by calculating Cronbach’s alpha. The 
reproducibility of the SF-Qualiveen was determined by calculating the intraclass correlation 
coefficient (ICC) for agreement of the repeated measurements. The limits of agreement 
(LOA) were determined. In general, differences in scores within the LOA can be interpreted 
as measurement error.14 
A post hoc subgroup analysis was performed to investigate construct- and criterion validity, 
internal consistency and reproducibility of the Dutch SF-Qualiveen in different subgroups 
based on level of SCI, ASIA (American Spinal Injury Association) Impairment Scale and 
manner of bladder emptying. 
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Statistical analyses
We aimed to include at least 50 patients and 50 controls to comply with the guidelines for 
validation of questionnaires.13 For the face-to-face interviews we aimed to include at least 
10 SCI patients. 
For the statistical analyses we used SPSS version 21. Descriptive results are presented as 
mean ± standard deviations for continuous data and counts and percentages for discrete 
data. Student’s T-tests were used to assess differences between groups for continuous 
variables and Chi-Square tests for categorical variables. Associations between variables 
were assessed using the Pearson’s correlation coefficient in case of a linear association. 
Cronbach’s alpha’s were calculated to determine the internal consistency. Cronbach’s alpha’s 
between 0.7 and 0.95 were considered good.13 The LOA were calculated as the mean change 
in scores of repeated measurements ± 1.96 x standard deviation (SD) of the changes.14 ICCs 
of 0.7 or higher were considered to represent good reproducibility.13 Statistical significance 
was assumed at a p-value of less than 0.05. 
RESULTS
66 SCI patients completed the questionnaires at baseline (‘test’). Seven patients did not 
return the second questionnaires while one declined further participation. The mean 
SF-Qualiveen score (test) of these patients was 1.81 ± 0.65. One patient was diagnosed 
with a malignant tumor and excluded. In total, 57 SCI patients completed the second 
questionnaires (retest) on average 12.7 (± 9.0) days after the first questionnaires and were 
included in the analyses. Characteristics of the study groups are displayed in Table 2. Most 
patients had a thoracic SCI, required a wheelchair for mobility and were dependent upon 
catheterization (intermittent or indwelling) to empty their bladder. The 50 controls were 
significantly younger than the SCI patients. The proportion of males and females was similar 
in both groups. 
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Table 2. Clinical characteristics
Patients Controls P-value
N 57 50
Age at examination 53.2 ± 14.6 42.3 ± 14.2 <0.001 
Sex Male
Female
37 (64.9%)
20 (35.1%)
26 (52.0%)  
24 (48.0%)
0.176
Years after SCI 13.1 ± 12.8
Level of SCI Cervical
Thoracic
Lumbar
15 (26.3%)
31 (54.4%)
11 (19.3%)
ASIA Impairment Scale A
B
C
D
23 (40.3%)
5 (8.8%)
7 (12.3%)
20 (35.1%)
Missing: 2 (3.5%)
Mobility Fully ambulatory
Limited walking
Wheelchair only 
4 (7.0%)
16 (28.1%)
35 (61.4%)
Missing: 2 (3.5%)
Manner of bladder 
emptying
(normal) voiding
Abdominal pressure
Total incontinence 
Intermittent catheterization
Indwelling catheter
5 (8.8%)
1 (1.8%)
1 (1.8%)
27 (47.4%)
22 (38.6%)
Missing: 1 (1.8%)
Results are presented as mean ± standard deviations for continuous data and counts and percentages 
for discrete data. ASIA Impairment Scale, American Spinal Injury Association Impairment Scale (A: 
Complete, B: Sensory incomplete, C: Motor incomplete - half of key muscle functions below the 
neurological level of injury have a muscle grade less than 3, D: Motor incomplete - at least half of key 
muscle functions below the neurological level of injury have a muscle grade > 3)15; SCI, Spinal Cord 
Injury
Validation process
Following the translation of the SF-Qualiveen into Dutch, 12 SCI patients and 11 MS patients 
were interviewed to assess content validity. The translated SF-Qualiveen was distributed to 
the patients. Thereafter, patients were asked whether the questions covered all the bladder 
problems that affected their quality of life. Both patient groups agreed on the importance 
of the questions and found it a complete measure that covered the broad range of bladder 
problems that they experienced. Furthermore, patients found the Dutch version clear and 
easy to complete. 
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The predefined hypotheses on construct validity were confirmed: 
1. Positive significant associations were found between both the total UDI-6 and the 
different domains of the UDI-6 which measure the severity of irritative, stress and 
obstructive/discomfort urinary symptoms and the total SF-Qualiveen scores in the 
patient group. (Table 3) The hypothesis that SF-Qualiveen scores of patients would 
be positively associated with the severity of urinary symptoms was confirmed. 
2. The mean of the total scores of the SF-Qualiveen for the patient group was 1.81 ± 
0.99 for the test and 1.80 ± 1.08 for the re-test while the control group reported a 
mean score of 0.34 ± 0.59 (P < 0.001). In an older subgroup of controls >40 years 
(n = 27, mean age 53.9 years) the mean total SF-Qualiveen score was 0.51. A 
significant difference in mean SF-Qualiveen scores between the patient group and 
the control group >40 years was found (P < 0.001).
A significant positive association between the SF-Qualiveen and the UDI-6 was found in 
both the patient (Table 3) and control group (r = 0.632 and P < 0.001). Criterion validity was 
hereby found to be good. Floor and ceiling effects were not found in the patient group for 
the total SF-Qualiveen score (Test: no patients had the lowest or highest possible score. Re-
test: 2% of the patients had the lowest and 2% had the highest possible score). As expected, 
a floor effect was found in the control group for the total SF-Qualiveen score: 50% of the 
controls had the lowest possible score. No ceiling effect was found in the control group 
(none had the highest possible score).
Table 3. Correlations between severity of urinary symptoms (UDI-6 domain scores) – and SF-
Qualiveen total scores in patient group
Test Re-test
UDI-6 – total score r = 0.663 and P < 0.001 r = 0.673 and P < 0.001
Severity of irritative urinary symptoms r = 0.596 and P < 0.001 r = 0.543 and P < 0.001
Severity of stress urinary symptoms r = 0.451 and P < 0.001 r = 0.424 and P = 0.001
Severity of obstructive/discomfort urinary 
symptoms
r = 0.521 and P < 0.001 r = 0.630 and P < 0.001
Pearson’s correlation coefficients were determined to assess the relationship between variables. UDI-
6, Urinary Distress Inventory-6.
Cronbach’s alpha’s of 0.89 (test) and 0.92 (re-test) indicated good internal consistency for 
the total SF-Qualiveen. (Table 4) The domains ‘bother with limitations’ and ‘feeling’ showed 
good internal consistency as well. Internal consistency of the domains ‘fears’ and ‘frequency 
of limitations’ was moderate. The ICCs for the repeated measurements of the test and re-
test for the SF-Qualiveen total score and domain scores showed good reproducibility (Table 
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5). Table 5 shows the limits of agreement (LOA) as well. Differences between -0.72 and 0.70 
can be interpreted as not clinically important. 
Table 4. Internal consistency – Cronbach’s alpha (n = 57 SCI patients)
Test Re-test
SF-Qualiveen total score 0.89 0.92
SF-Qualiveen domains:
       Bother with limitations 0.87 0.90
       Fears 0.53 0.73
       Feeling 0.80 0.84
       Frequency of limitations 0.55 0.75
SCI, Spinal Cord Injury
Table 5. Reproducibility of SF-Qualiveen
ICC LOA
SF-Qualiveen total score 0.94 -0.72 to 0.70
Bother with limitations 0.90  -1.12 to 1.00
Fears 0.92 -0.97 to 0.99
Feeling 0.87 -1.27 to 1.23
Frequency of limitations 0.79 -0.72 to 0.70
ICC, Intraclass Correlation Coefficient; LOA, Limits of Agreement
In Table 6 the results of the post hoc subgroup analyses based on level of SCI, ASIA 
Impairment Scale and manner of bladder emptying are shown. Most subgroups showed a 
positive significant association between the SF-Qualiveen total scores and the UDI-6 score 
and a significant difference in mean SF-Qualiveen scores compared to the control group, 
indicating good criterion and construct validity. Cronbach’s alpha’s of >0.79 and ICCs >0.86 
confirmed good internal consistency and reproducibility for the different subgroups. 
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DISCUSSION
In this study we introduced the SF-Qualiveen in a SCI patient group. We showed good 
content-, construct- and criterion validity, internal consistency and reproducibility of the 
SF-Qualiveen in this patient group. We conclude that the SF-Qualiveen can be used in the 
Netherlands to evaluate the urinary-specific quality of life in SCI patients. 
The ICCs of the repeated measurements in this study (ranging from 0.79 to 0.94) showed 
good reproducibility for the total SF-Qualiveen and the separate domains, although they 
were somewhat lower than the ICCs found in the French and English SF-Qualiveen validation 
study in MS patients (0.88 to 0.94).7 The ICCs as found in the present study are comparable 
to the Dutch validation study of the SF-Qualiveen in MS patients (0.72 to 0.90).9 The Dutch 
SF-Qualiveen showed to be a reliable instrument for SCI patients. 
Internal consistency for the total SF-Qualiveen was good. Cronbach’s alpha’s of 0.53 to 0.75 
for the separate domains ‘fears’ and ‘frequency of limitations’ showed moderate internal 
consistency. This is consistent with results from the Dutch validation study of the SF-
Qualiveen in MS patients.9 Internal consistency was not described in the French and English 
validation study of the SF-Qualiveen. These study results indicate that the four domains 
of the Qualiveen-30 cannot be confirmed in the SF-Qualiveen, probably due to the small 
number of questions (two) in every domain. This strengthens the previous recommendation 
of Reuvers et al.9 to not use the separate domains of the SF-Qualiveen, but only the total 
SF-Qualiveen. 
The results of the subgroup analyses suggest that the Dutch SF-Qualiveen has equal 
measurement properties for SCI patients with different levels of SCI, ASIA Impairment 
statuses and manners of bladder emptying. Not finding a statistical significant correlation 
between the SF-Qualiveen scores and UDI-6 scores in the ASIA group B (n = 5) and C (n = 
7) and the group without catheter usage (n = 7) could be explained by the lack of statistical 
power in the small patient groups due to the post hoc analysis.
Most SCI patients experience bladder problems as a consequence of damage to the spinal 
cord.1, 3 These bladder problems have a negative effect on patients’ quality of life.4 In the 
urological management of SCI patients optimization of the quality of life is an important 
aspect as mentioned in the EAU guidelines.5 Therefore, it is essential for healthcare 
professionals to be informed about a patients’ present urinary-specific quality of life. The SF-
Qualiveen is now available to objectively assess this topic in the Dutch SCI population. Only 
after being informed about present urinary-specific quality of life, an optimal treatment 
plan can be defined. 
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For the future we suggest that urology and rehabilitation departments in the Netherlands 
implement the Dutch-version SF-Qualiveen in the urological management of SCI patients. 
The Dutch SF-Qualiveen is now available as a measurement tool. Further research should 
be aimed at determining its responsiveness to treatment. Once this has been established as 
sufficient, the Dutch SF-Qualiveen may be used to evaluate the effect of treatments on the 
urinary-specific quality of life in clinical and research settings. 
A question that arises is if we can recommend the use of the SF-Qualiveen in all neuro-
urological patients. D’Ancona et al.16 included, next to 33 SCI and eight MS patients, 
10 patients with meningomyelocele (MMC) in the validation study of the Portuguese 
Qualiveen-30. Results of the different patient groups were not separately described. The 
authors state that MMC patients would have the same concerns regarding urinary-specific 
quality of life as SCI and MS patients. However, there might be a difference in the experience 
of patients with congenital neurological diseases such as MMC compared to patients with 
acquired diseases like SCI and MS. Therefore, it would be valuable to study the usefulness of 
the SF-Qualiveen in congenital neurological patients. 
It is questionable if our Dutch version SF-Qualiveen validated in the Netherlands can be used 
in other Dutch speaking countries such as Belgium and South-Africa. Although the language 
is technically the same, wording and expressions can be different as well as cultural habits. 
Therefore, we recommend a new validation process before introducing the Dutch SF-
Qualiveen in other Dutch language countries. 
A strength of this study was the homogeneous patient group of SCI patients. Study results 
therefore provide a clear view of the validity and reliability of the SF-Qualiveen in this 
patient group. Furthermore, as this study was conducted at the outpatient clinics of urology 
of a general hospital and rehabilitation clinic, the SF-Qualiveen may be considered suitable 
for the use in both settings. 
A limitation of the study was that eight of 66 patients (12.1%) were excluded because they 
did not complete the second questionnaire. This may have introduced a selection bias. 
However, the SF-Qualiveen scores (test) of these patients were similar to those of the 
included patients. Therefore, the selection bias may not be an important issue. Another 
limitation is that no other validated urinary-specific quality of life measure for neuro-
urological patients is available to serve as a perfect gold standard to determine the criterion 
validity of the SF-Qualiveen. In the absence of a perfect gold standard, we chose the 
UDI-6, a urinary tract symptom inventory, which may have been suboptimal. In addition, 
criticism could be raised on the age difference between the patient and control group. To 
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investigate one of the hypotheses on construct validity, we used data of a control group. 
We hypothesized that scores of the SF-Qualiveen in the patient group would be higher than 
scores in the control group. As a consequence of using earlier collected data, the age of 
the patient and control group were not matched and we found a statistical significant age 
difference between the groups. However, we did not expect this age difference to influence 
outcomes. We assumed that non-neuro-urological patients of the control group, regardless 
of their age, would have lower scores on a measure that evaluates the urinary-specific 
quality of life (developed for the use in neuro-urological patients) than the neuro-urological 
patient group. This expectation was strengthened by the fact that we also found a statistical 
significant difference in SF-Qualiveen scores between the patient group and the older 
control group (>40 years). 
CONCLUSIONS
From this study we can conclude that the Dutch SF-Qualiveen is valid and reliable to measure 
the urinary-specific quality of life in SCI patients. This short questionnaire, which is easy to 
complete, can be a valuable instrument. We suggest to use the total Dutch SF-Qualiveen for 
evaluation of the urinary-specific quality of life in SCI patients. 
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CHAPTER 5
Maximum urethral closure pressure increases 
after successful adjustable continence therapy 
(ProACT) for stress urinary incontinence after 
radical prostatectomy
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ABSTRACT
Objective: To evaluate changes of the urethral pressure profile (UPP) after implantation 
of adjustable continence therapy (ProACT), a minimally invasive procedure in which 2 
volume-adjustable balloons are placed periurethrally for treatment of male stress urinary 
incontinence. The working mechanism of the ProACT to achieve continence has not been 
fully understood. We hypothesized that successful treatment with ProACT improves urinary 
continence by inducing a significant increase in static urethral pressure. 
Materials and methods: We included patients who underwent UPP before and after ProACT 
implantation. UPPs were initially performed with the Brown-Wickham water perfusion 
method and later with the T-DOC Air-Charged catheter method. Pre- and postoperative 
UPPs and International Prostate Symptom Scores were evaluated. UPP measurements of 
successfully (no or 1 precautionary pad per day) and unsuccessfully treated patients were 
compared.
Results: Twenty-seven patients were included in the study; 23 patients were successfully 
and 4 patients were unsuccessfully treated. Maximum urethral closure pressure (MUCP) 
increased significantly from median 58.0 to 79.0 cm H2O in the successfully treated group 
(P = .001). Within the subgroup of unsuccessfully treated patients, MUCP did not change 
significantly (P = .715). The change in MUCP was statistically significantly different between 
the successful and unsuccessful group (P = 0.034). Total score of the International Prostate 
Symptom Scores did not change significantly after ProACT implantation (P = .097). 
Conclusions: Successful treatment with ProACT is associated with a significant increase 
of MUCP. This implies that increased static urethral pressure contributes to the working 
mechanism of the ProACT device to achieve continence. 
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INTRODUCTION
Postprostatectomy incontinence (PPI) is a common complication after radical prostatectomy 
(RP) that can cause great distress.1 One year after RP, the incidence of urinary incontinence 
is 9%-16% depending on the definition used and surgical technique.2, 3 Most of the PPI 
patients suffer primarily from stress urinary incontinence (SUI). The maximum urethral 
closure pressure (MUCP) and functional profile length (FPL) are decreased after RP, 
presumably caused by the loss of forces normally generated by the prostate and sphincter, 
and are associated with regaining continence.4, 5 Although implantation of an artificial 
urinary sphincter is still the gold standard treatment for moderate to severe SUI after RP, 
less invasive techniques have become more available.6 
One such technique is the Adjustable Continence Therapy (ProACT, Uromedica, Minneapolis, 
MN). This implies implantation of a device consisting of 2 periurethrally placed volume-
adjustable balloons. ProACT implantation achieved continence (defined as the use of no or 
1 precautionary pad) in 60%-80% of patients7-11 and quality of life index scores for urinary 
incontinence improved by 31-48 points (score range 1-100).8-10, 12 
The working mechanism of the ProACT has not been fully understood. Other continence 
devices like the male sling13-15 elevate the MUCP after (successful) treatment. Utomo et al. 
16 demonstrated that the urethral resistance during voiding had increased in men who were 
successfully treated with ProACT for SUI after RP. We hypothesized that the ProACT induces 
changes of the static urethral pressure profilometry (UPP), especially an increase of MUCP, 
and that this mechanism contributes to regaining continence. The objective of this study 
was to evaluate the UPP and International Prostate Symptom Score (IPSS) measures before 
and after ProACT implantation in patients with SUI after RP.
MATERIALS AND METHODS
Subjects
We reviewed the medical charts of patients who had undergone ProACT implantation for 
SUI after RP at our institution. We included patients for whom a pre- and postoperative 
UPP was available. Patients who underwent urinary tract surgery between the pre- and 
postoperative measurements were excluded. This study was approved by the local ethic 
committee.
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Intervention
The first ProACT implantation at our institution was performed on May 2007. Since then, all 
implantations were done by one surgeon (BFMB). The procedure was performed as firstly 
described by Hubner and Schlarp11. In the first cohort of patients, a rigid 19F cystoscope was 
used, and in the second cohort from April 2014, a flexible cystoscope was used. Patients 
initially visited the department of Urology every 3-4 weeks after implantation. Balloon 
volume adjustments were made by percutaneous scrotal needle puncture with a maximum 
of 1 mL on each side if patients reported persistent SUI. Adjustments were made until 
continence was achieved, until the balloons were filled with a maximum of 8 mL or until 
there was any other reason to stop filling the balloons (eg, symptoms of obstructed voiding, 
infection, dislocation of the balloons).
Design 
Relevant data were retrospectively retrieved from the patients’ medical files, including the 
IPSS.17 Urinary incontinence was classified as mild (1 or 2 pads per day), moderate (3 or 4 
pads per day), or severe (5 or more pads per day or use of condom catheter). The treatment 
was defined as ‘successful’ when patients used no or 1 precautionary pad per day after 
balloon adjustments. 
Methods of measurement
UPPs were performed by one physician (JG) pre- and postoperatively after the balloon 
volume adjustments were completed. 
Two UPP techniques were used. In a first cohort of patients, we used the Brown-Wickham 
water perfusion method.18, 19 Two consecutive UPPs were performed. A side-hole 9F water 
perfusion catheter oriented at the 12 o’clock position was inserted into the bladder and 
withdrawn through the urethra (withdrawal rate 1 mm/s and perfusion rate 1 mL/min). 
Rectal pressure was monitored with an 8F tube. From 2011, the T-DOC Air-Charged 7F 
catheter (Laborie, Mississauga, Canada) method20 was used. One UPP was performed in 
every patient pre- and postoperatively. After inserting the catheter into the bladder, the 
catheter balloons were inflated. The catheter was withdrawn at a speed of 1 mm/s. In 
each patient, the pre- and postoperative measurements were performed using the same 
technique. The measurements were done at a bladder volume of 100 mL. The FPL and 
MUCP were derived from the UPPs. 
AUDACT software version 7.11 (Andromeda Medizinische Systeme GmbH, Taufkirchen, 
Germany) was used to measure and analyze UPP data. 
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Analysis
Statistical analyses were performed with the statistical package SPSS 21 version. A P value 
of < 0.05 was considered to reflect statistical significance. Descriptive results are presented 
as median and interquartile range for continuous data, and as counts and percentages for 
discrete data. We used the Wilcoxon signed-rank test for continuous variables to compare 
preoperative and postoperative data within groups. The Mann-Whitney U test for continuous 
variables and Pearson’s Chi-Square test for discrete variables were used to compare variables 
between groups. Spearman rank correlation was used to test the association between 2 
variables. 
RESULTS
At our institution, 29 patients underwent UPP before and after ProACT implantation between 
December 2008 and March 2015. Two patients underwent urinary tract surgery between 
the preoperative and postoperative UPP and were excluded. Basic characteristics of the 
included men are displayed in Table 1. We compared the patient characteristics between 
the group with a successful clinical outcome (n = 23) and the group with an unsuccessful 
outcome (n = 4). The successful group had a significantly lower number of balloon volume 
adjustments than patients in the unsuccessful group (P = .001). We found no further 
statistically significant differences between the groups. 
Table 1. Patient characteristics
Complete group Successful group Unsuccessful group
N 27 23 4
Age 65.0 (62.0-71.0) 65.0 (62.0-71.0) 66.0 (60.5-75.3)
Body weight (kg) 85.0 (83.0-92.0) 85.0 (83.0-92.0) 87.5 (78.5-93.5)
Balloon volume adjustments 
(number) 3.0 (1.0-5.0) 3.0 (1.0-4.0) 7.5 (5.5-8.0)
Interval prostatectomy – 
ProACT (months) 29.0 (20.0-74.0) 33.0 (20.0-74.0) 25.0 (17.3-151.3)
Interval ProACT – UPP 
postoperatively (months) 7.0 (5.0-10.0) 6.0 (4.0-9.0) 10.0 (7.0-17.5)
Incontinence severity before 
ProACT
- Mild: 1-2 pads/24h
- Moderate: 3-4 pads/24h
- Severe: > 4 pads/24h
-  8 (29.6%)
-  13 (48.1%)
-  6 (22.2%)
- 8 (34.8%)
- 11 (47.8%)
- 4 (17.4%)
- 0 (0%)
- 2 (50.0%)
- 2 (50.0%)
UPP measurement method
-Brown-Wickham
-T-DOC air charged catheter
-  11 (40.7%)
-  16 (59.3%)
- 10 (43.5%)
- 13 (56.5%)
- 1 (25.0%)
- 3 (75.0%)
ProACT, adjustable continence therapy; UPP, urethral pressure profile.
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Changes of the UPP After ProACT Implantation
The MUCP and FPL increased significantly after successful treatment with ProACT (Table 2). In 
contrast, both parameters did not significantly change within the subgroup of unsuccessfully 
treated patients. The change in MUCP, from preoperative to postoperative, was median 13.0 
cm H2O in the successfully treated group and 4.5 cm H2O in the unsuccessfully treated 
group. This increase was statistically significantly different between the groups (P = .034). 
The change in FPL was not significantly different between the groups (P = .576). A typical 
example of a UPP after successful treatment with ProACT is shown in figure 1.  
Figure 1. Typical example of a UPP before and after successful treatment with ProACT. Pclo, urethral 
closure pressure; ProACT, adjustable continence therapy; Pura, urethral pressure; Pves, intravesical 
pressure; UPP, urethral pressure profile. 
The UPP measurements were compared between the 2 measurement methods. MUCP 
increased significantly after ProACT in both groups. (Table S1) No significant differences 
were found in baseline MUCP (P = .544), postoperative MUCP (P = .716), and change in 
MUCP (P = .610) between the 2 measurement methods. FPL increased significantly after 
ProACT in the Brown-Wickham group, whereas it did not change significantly in the T-DOC 
subgroup. (Table S1) Although a significant difference was found in the postoperative FPL (P 
= .017), the preoperative FPL (P = .071) and the change in FPL (P = .645) were not significantly 
different between the Brown-Wickham water perfusion and the T-DOC air charged catheter 
subgroup.
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IPSS
IPSS total score and IPSS questions 5 and 6 scores (which are assumed to reflect voiding 
problems) did not change after ProACT implantation (table 3). 
Table 3. IPSS scores before and after ProACT implantation. 
Preoperative Postoperative P*
IPSS - total score 11.0 (5.5 - 15.5)
Missing: 10
7.0 (4.0 – 11.0)
Missing: 0
.097
IPSS - question 5 0.5 (0 – 3.0)
Missing: 9
1.5 (0 – 3.3)
Missing: 1
.298
IPSS - question 6 0 (0 – 1.0)
Missing: 9
0 (0 – 2.0)
Missing: 1
.277
IPSS – QoL question 8 4.0 (4.0 – 5.0)
Missing: 7
1.0 (1.0 – 2.0)
Missing: 0
< .001
IPSS, International Prostate Symptom Score. Data are displayed as median (Interquartile Range). The 
number of missing values per item is displayed. IPSS question 5: How often have you had a weak 
urinary stream? IPSS question 6: How often have you had to strain to start urination? IPSS – QoL 
question 8: If you were to spend the rest of your life with your urinary condition just the way it is now, 
how would you feel about that? * P, Wilcoxon signed-rank test to assess changes in outcomes before 
and after ProACT implantation. Bold values indicate a statistically significant correlation with a P-value 
of < 0.05.
No statistically significant correlations were found between the postoperative IPSS total 
score and postoperative MUCP (rho = -0.086 and P = .670) and FPL (rho = 0.004 and P = 
.984). In addition, no correlations were found between the postoperative IPSS question 5 
score and the postoperative MUCP (rho = -0.303 and P = .133) and FPL (rho = -0.040 and 
P = -.847), nor between postoperative IPSS question 6 score and postoperative MUCP (rho = 
0.163 and P = 0.426) and FPL (rho = 0.310 and P = 0.124). 
IPSS question 8, a quality of life due to urinary symptoms question, increased significantly 
from median 4 (mostly dissatisfied) preoperatively to 1 (pleased) postoperatively (table 3). 
COMMENT
In this study it was found that static UPP values had increased after ProACT implantation 
in men who suffered from SUI after RP. MUCP significantly increased in the successfully 
treated group, whereas it did not in the unsuccessfully treated patients. In addition, the 
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change in MUCP was statistically different between the groups. This suggests that the 
increase in static urethral pressure is an important factor to regain continence. Although 
FPL significantly increased postoperatively in the successfully treated group and did not 
reach the significance level in the unsuccessfully treated group, the change in FPL was not 
statistically different between the groups. 
No other studies have analyzed the effect of ProACT implantation on UPP. However, 
UPP changes have been studied in the context of other male continence devices, such 
as slings13-15. Horstmann et al.13 investigated urodynamic findings in patients before and 
after bulbourethral composite suspension. They included 10 successfully treated patients 
and performed UPP by the air-charged catheter method. An increase in MUCP from 40 
to 58 cmH2O and an increase in FPL from 31 to 40 mm was found. When comparing the 
successfully treated group in our study with the patients in Horstmann et al’s study, pre- as 
well as postoperative MUCP values were higher in our study (they changed from 58 cm H2O 
preoperatively to 79 cm H2O postoperatively). Also in the T-DOC subgroup in our study, 
MUCP values were higher. The FPL measurements and changes in the Horstmann et al. study 
are comparable to the results we found in our study, where FPL changed from 30 mm to 43 
mm in the successfully treated group. The different outcomes between these two studies 
can be explained by the used definitions of success. Horstmann et al. defined success as a 
> 50% reduction in pad use. Our definition of success (dry or 1 pad for precaution) is more 
strict.
Wadie14 described UPP changes (using the water perfusion measurement method) in 40 
male patients after retropubic bulbourethral sling placement. Successfully (in this study 
defined as no pad use and a negative stress test) and unsuccessfully treated patients were 
included. MUCP changed from 57 cmH2O preoperatively to 100 cmH2O postoperatively, 
and FPL changed from 21 mm to 52 mm. Although these changes seem numerically relevant, 
they did not reach statistical significance. 
Rehder and Gozzi15 reported on the outcome of 20 patients treated by transobturator sling 
suspension. UPPs were performed in 5 patients. It is unclear if the patients who underwent 
UPPs were successfully or unsuccessfully treated and which measurement method was 
used. Although it is hypothesized that the transobturator sling does not compromise the 
urethra, MUCP changed from 13 cmH2O preoperatively to 86 cmH2O postoperatively. FPL 
changed from 3 mm to 17 mm. Baseline MUCP and FPL in our study were higher than in 
the patients studied by Rehder and Gozzi. It is difficult to compare the results because the 
outcome of treatment in these patients and the used measurement method are unknown. 
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The urethral pressure is derived from the distensibility of the urethra, the forces of the 
surrounding tissues (eg, the prostate and the sphincter) and the cross-sectional area of the 
urethra.5 It is known that the MUCP is decreased postprostatectomy and that MUCP values 
are higher in men who regain continence than in men who remain incontinent.4 We found an 
increase in MUCP after successful treatment with the ProACT device. Bilateral compression 
of the urethra by the balloons might be responsible for this increase and could partially 
replace the forces normally generated by the prostate and sphincter. This implies that an 
increase in the static urethral pressure contributes to the working mechanism of ProACT. 
The regain of continence may not be fully explained by the increase of MUCP, because 
such an increase did not occur in all successfully treated patients. An additional factor 
that might contribute to the continence mechanism is the displacement of the urethra 
toward the pubic bone by the balloons. This mechanism has been described after 
placement of a transobturator sling with minimal tension in male cadavers (presumably 
not postprostatectomy).15 However, periurethral fibrotic tissue after prostatectomy makes 
displacement at the level of the balloons toward the pubic bone less probable. It could be 
hypothesized that the ProACT induces a displacement of the urethra, but this seems less 
important than the direct compressive effect on the urethra. 
The role of FPL in the working mechanism of ProACT remains unclear. The observed increase 
of FPL in the small group of unsuccessfully treated men (although not significant), the 
insignificant difference in change in FPL between the successful and unsuccessful groups, 
and the difference in values obtained with the 2 techniques hamper a straightforward 
interpretation of results.
We evaluated the IPSS, a patient-reported outcome measure, with special interest in the 
questions reflecting obstructive voiding symptoms and patient satisfaction. IPSS did not 
significantly change after ProACT implantation. This suggests that ProACT is not associated 
with the occurrence of obstructive voiding symptoms. This is of clinical importance for future 
use of the ProACT. The occurrence of voiding symptoms did not correlate with postoperative 
MUCP and FPL. Patients’ satisfaction with their urinary condition (IPSS question 8) changed 
from mostly dissatisfied preoperatively to pleased postoperatively. This indicates that the 
most important treatment goal, patient satisfaction, was realized in most patients. 
This is the first study that describes UPP changes after ProACT implantation and it thus 
contributes to the understanding of the working mechanism of ProACT. This is of relevance 
for the development of future devices and it could contribute to understanding the 
mechanism of PPI as well. 
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A limitation of our study is the use of 2 different UPP measurement techniques. Although 
both the Brown-Wickham water perfusion catheter method18, 19, 21 and the T-DOC air-
charged catheter method20 have been separately proven to accurately measure the UPP, it 
is unknown if they can be used interchangeably. No comparing trials between the 2 used 
techniques are available. Comparing the results obtained with the 2 techniques in our study, 
we only found a statistically significant difference in the postoperative FPL values. We used 
the same technique pre- and postoperatively in each patient. Intrapatient comparisons 
are therefore reliable. Another limitation of the study is that the IPSS is not validated in 
this study population. The IPSS is validated in patients with benign prostate hypertrophy. 
The reason for using the IPSS in our practice during and after balloon adjustments of the 
ProACT is that it informs us on the occurrence of obstructive voiding complaints. No such 
questionnaire is validated for this specific patient group. Other limitations of the study are 
its retrospective design and the relatively small study group.
CONCLUSIONS
We conclude that successful treatment with ProACT is associated with a considerable and 
significant increase of MUCP. This implies that increased static urethral pressure contributes 
to the working mechanism of the ProACT device to achieve continence. 
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SUPPLEMENTARY MATERIAL S1
Supplementary material S1. UPP parameters before and after ProACT implantation. Brown-Wickham 
water perfusion method vs. T-DOC Air-Charged catheter method.
Brown-Wickham subgroup
(Successful N = 10,
Unsuccessful N = 1)
T-DOC subgroup
(Successful N = 13
Unsuccessful N = 3)
Preoperative Postoperative P* Preoperative Postoperative P*
MUCP 
(cmH2O)
58.0
47.0-85
79.0
56.0-166.5
0.041 60.0
45.5-76.0
75.0
51.0-104.3
0.021
FPL (mm) 24.9
21.4-37.5
32.3
20.9-45.5
0.013 30.0
26.1-54.4
45.4
36.1-59.6
0.121
Data are displayed as median and Inter Quartile Range. MUCP = Maximum Urethral Closure Pressure, 
FPL = Functional Profile Length. P* = Wilcoxon signed rank test to assess changes in outcomes before 
and after ProACT implantation.
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ABSTRACT
Aims: To evaluate the long-term outcome of appendicovesicostomies and to present the 
frequency and timing of complications needing re-intervention.
Methods: In this retrospective study we included patients in whom an appendicovesicostomy 
was created at our institution between 1993 and 2011. Patients with a follow-up less than 
1 year were excluded. Patient characteristics and conduit-related complications requiring 
re-intervention were collected. 
Results: One hundred and twenty-eight patients were included with mean age at initial 
surgery of 10.1 ± 3.9 years. Two thirds of the children had underlying neurogenic disease. The 
mean follow-up was 10.1 ± 4.8 years. All but one patient continued to use the catheterizable 
channel. Re-intervention for conduit-related complications was necessary in 32.0% of the 
patients. A second, third and fourth re-intervention was required in respectively 10.9%, 
2.3% and 1.6%. The commonest complications were cutaneous/fascial stenosis in 14.8%, 
stenosis at conduit-bladder level in 9.4%, and stomal incontinence in 6.3% of the patients. 
The most performed re-interventions were stoma revision (in 16.4% of the patients), conduit 
revision (10.2%), and dilatation of a stenotic tract (4.7%). 63.3% of the re-interventions was 
superficial and/or endoscopic. The peak incidence of re-interventions was in the 1st year 
after conduit construction and decreased yearly. 
Conclusions: Our study gives an overview of patients and their conduits developing from 
prepubertal children to young adults. During a mean follow-up of 10.1 years, roughly one third 
of the patients needed a re-intervention. We conclude that an appendicovesicostomy is an 
effective and durable treatment for whom transurethral clean intermittent catheterization 
is not feasible. 
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INTRODUCTION
For children with irreversible lower urinary tract dysfunction, for whom transurethral 
clean intermittent catheterization (CIC) is not feasible, a continent catheterizable conduit 
can be a solution for bladder drainage. Mitrofanoff appendicovesicostomy1 and Monti 
ileovesicostomy2 are the most common created continent catheterizable channels. 
Although short-term outcomes, complications and re-interventions after continent 
catheterizable conduit construction are commonly reported,3-10 the long-term follow-up and 
thereby the durability of conduits is still under-documented.11-14 Previous long-term follow-
up studies included small study populations,11, 13 heterogenic study populations,13 and a 
mean follow-up of less than 10 years.12-14 The long-term follow-up of paediatric patients 
after continent catheterizable conduit construction is of particular interest, because of their 
long life expectancy.
For this reason we evaluated the long-term outcome of continent catheterizable 
conduits. We present the frequency and time of occurrence of complications needing re-
intervention in a group of 128 paediatric patients with a mean follow-up of 10 years after 
appendicovesicostomy construction. 
MATERIALS AND METHODS
We reviewed the medical charts of all paediatric patients who had undergone surgical 
construction of a continent catheterizable conduit using appendix at our institution 
between 1993 and 2011. Patients with a minimum follow-up of 1 year after initial surgery 
were included in our study. 
Surgical procedures were performed as described by Mitrofanoff to create an 
appendicovesicostomy.1 If, for a concurrent procedure, it was necessary to open the bladder 
(i.e. augmentation), a submucosal tunnel was created. In patients with no concurrent 
procedure the detrusor tunnel was created according to the Lich-Gregoire technique.15 In 
the majority of cases, stomas were constructed umbilical by using a V-shaped skin flap. 
Patients were initially followed up every 3 months. If a conduits’ condition was stable, the 
frequency of visits was lowered. CIC was started 4-6 weeks postoperatively, using disposable 
catheters 12-14 Fr. Antegrade colonic enema (ACE) stoppers (a silicone plug) were not 
routinely prescribed. 
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Information about demographics, underlying diagnosis, surgical procedure, conduit related 
complications and their re-interventions (performed under general anaesthesia) and follow-
up duration was retrospectively retrieved from the medical files.
Statistical analyses were performed with the statistical package SPSS 21 version. A P-value of 
< 0.05 was considered to reflect statistical significance. Descriptive results are presented as 
mean ± standard deviation for continuous data and as counts and percentages for discrete 
data. The Chi-Square test was used to compare the frequency of re-interventions between 
groups for categorical variables. Kaplan-Meier curves were generated to display the time to 
re-interventions and the re-intervention free survival. 
RESULTS
At our institution 131 paediatric patients underwent surgery to construct an 
appendicovesicostomy between 1993 and 2011. Three patients had a follow-up of < 1 
year and were excluded. We included all other 128 patients for as long as they were under 
treatment at our hospital. The mean follow-up was 10.1 ± 4.8 years and ranged from 
minimum 1.9 to maximum 21.8 years. After 5, 10 and 15 years respectively 111, 59 and 
26 patients were still in follow-up. At the end of follow-up the mean age was 20.7 ± 6.3 
years and ranged from minimum 8.1 to maximum 35.8 years. Currently, 93/128 patients 
(72.6%) are still in follow-up at our institution. 2/128 (1.6%) died of unrelated diseases, 
care for 27/128 patients (21.1%) was transferred to another hospital (most at the time of 
transition from paediatric to adult care) and 6/128 patients (4.7%) were lost to follow-up 
due to unknown reasons. Mean follow-up of the 35 patients who were lost to follow-up was 
quite long: 7.7 ± 3.5 years and the mean age at the final follow-up visit was 18.3 ± 5.7 years. 
Patient characteristics are displayed in table I. The gender distribution was almost equal. 
The underlying diagnosis was neurogenic bladder dysfunction in 85 (66.4%) and non-
neurogenic bladder dysfunction in 43 (33.6%). In the neurogenic group myelomeningocele 
was the commonest diagnosis (75.3%), followed by tethered cord, spinal cord injury and 
spastic tetraplegia. Bladder exstrophy was the most common non-neurogenic diagnosis 
(55.8%), followed by cloacal malformation, epispadias, Prune belly syndrome and traumatic 
lesions of the lower urinary tract. Bladder neck surgery was performed as a concurrent 
procedure in 57.1% of the patients and bladder augmentation in 69.5%. In all patients the 
aim of treatment was to create a high-volume, low-pressure reservoir. Other concurrent 
procedures were reimplantation of a ureter, urethral reconstruction and Botulinum toxin 
injections in the bladder. 
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Table I. Patient characteristics of 128 patients.
Age at conduit creation 10.1 ± 3.9 years
Gender Male
Female
68 (53.1%)
60 (46.9%)
Underlying diagnosis Neurogenic
Non-neurogenic
85 (66.4%)
43 (33.6%)
Concurrent procedures None 
Augmentation (alone)
Augmentation + bladder neck surgery
Bladder neck surgery (alone)
Other
18 (14.1%)
34 (26.6%)
55 (43.0%)
18 (14.1%)
3 (2.3%)
Stoma location Umbilical 
Lower abdominal quadrant
107 (83.6%)
21 (16.4%)
Mean ± standard deviation and number (percentage), are given where appropriate.
One hundred and twenty-seven of 128 patients (99.2%) continued to use their catheterizable 
channel for bladder emptying. In one patient the conduit could not be preserved due to 
postoperative bowel strangulation around the stoma resulting in ischemia of the channel. 
Forty-one of 128 patients (32.0%) underwent a re-intervention for conduit-related 
complications. A second, third or fourth re-intervention was necessary in respectively 
10.9%, 2.3% and 1.6% of patients. The commonest conduit-related complications requiring 
re-intervention were cutaneous/fascial stenosis in 14.8%, stenosis at conduit-bladder level 
in 9.4% and stomal incontinence in 6.3% of the patients. In total 60 re-interventions were 
performed for conduit related complications in 41 patients (table II). 
The mean age at re-intervention was 14.9 ± 5.4 years. The most performed re-interventions 
were stoma revision (in 16.4% of the patients), conduit revision (including re-implantation of 
the conduit into the bladder) (10.2%), dilatation of a stenotic tract (4.7%), and replacement 
of the conduit (3.9%). Other re-interventions were excision of the conduit and drainage of 
a parastomal abscess. 
Three of the six patients who underwent dilatation of a stenosis needed a second surgical 
re-intervention to treat the stenosis.
Thirty-eight of the 60 (63.3%) re-interventions were superficial and/or endoscopic: stoma 
revisions, dilatations, excision of polyps, bulking agent for stomal incontinence and 
endoscopic placement of an indwelling catheter. 
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Table II. Re-interventions and their indications. 
Re-interventions Number
Stoma revision
Indication: 
- cutaneous/fascial stenosis (20)
- fascial defect (2)
- mucosal prolapse (1)
- other (1)
24
Revision conduit
Indication: 
- incontinence (8)
- stenosis conduit-bladder (6)
14
Dilatation of stenosis
Indication:
- cutaneous/fascial stenosis (3)
- stenosis conduit-bladder (3)
6
Replacement conduit
Indication: 
- stenosis conduit-bladder (4)
- other (1)
5
Bulking agent conduit
Indication: stomal incontinence (3)
3
Endoscopic placement of an indwelling catheter
Indication: other catheterization problems (3)
3
Excision polyps
Indication: polyps (2)
2
Other 3
TOTAL 60 re-interventions in 41 patients
Figure 1 displays the occurrence and timing of the first re-intervention. After 1 year the 
risk of having had a re-intervention is 12.5%. After 5, 10 and 15 years, the cumulative risk 
of having had a re-intervention respectively is 22.9%, 32.7% and 36.5%. Fourteen patients 
needed a second, three patients needed a third and two patients needed a fourth re-
intervention during follow-up. Three of 19 second, third and fourth re-interventions (15.8%) 
were performed in the 1st year after appendicovesicostomy construction. Ten of 19 of these 
re-interventions (52.6%) were performed between the 2nd and 5th year of follow-up and 6 
of 19 (31.6%) re-interventions were performed after 5 years. Considering all 60 performed 
re-interventions, the peak incidence was in the first year after conduit formation, i.e., 
31.7% of all re-interventions, and decreased thereafter. With 102 of 128 patients (79.7%) 
in follow-up, only 12/60 (20.0%) re-interventions were performed after 6 years. Conduit-
bladder stenosis was the commonest late (after 6 years) complication (41.7%), followed by 
cutaneous/fascial stenosis (16.7%) and stomal incontinence (16.7%). The most performed 
re-interventions after 6 years were conduit revision (41.7%) and stoma revision (25.0%). 
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Figure 1. Timing of re-interventions
Kaplan-Meier curves represent data on the re-intervention free survival distribution.
Analysis revealed no significant differences in complication rate between male and female 
patients, neurogenic versus non-neurogenic underlying diagnosis, patients with or without 
augmentation and between the various stoma locations (Table III). 
Table III. Number of patients needing re-intervention in different groups
Male 
23/68 (33.8%)
vs Female
18/60 (30.0%) P = 0.644
Neurogenic
28/85 (32.9%)
vs Non-neurogenic
13/43 (30.2%) P = 0.756
Augmentation
26/89 (29.2%)
vs No augmentation
15/39 (38.5%) P = 0.302
Umbilical stoma
35/107 (32.7%)
vs Lower abdominal quadrant stoma
6/21 (28.6%)
P = 0.710
Statistical significances of different variables were explored using Chi-Square Tests.
DISCUSSION
During a mean follow-up of 10.1 years, roughly one third of the children with an 
appendicovesicostomy required a re-intervention. The commonest complications were 
cutaneous/fascial stenosis, stenosis at conduit-bladder level, and stomal incontinence. The 
most frequent re-interventions were stoma revision, conduit revision and dilatation of a 
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stenosis. In 63.3% of cases, the re-interventions were superficial and/or endoscopic. After 
conduit-replacement in five patients in the study group, all but one patient continued to 
catheterize the conduit. The peak incidence of re-interventions was in the 1st year after 
conduit formation and decreased yearly. 
About 32.0% of the patients required a re-intervention after a mean follow-up of 10.1 years. 
This is in line with the literature with a long-term follow-up. In a study by Rubenwolf et al.13 
with a median follow-up of 7.3 years, 39% of the patients required a re-intervention for stoma-
related complications after initial surgery (continent urinary diversion and enterocystoplasty). 
Leslie et al.12 reported a re-intervention rate of 39% after a follow-up of 5.8 years in a study 
population of 169 children with a continent catheterizable channel (Mitrofanoff or Monti). 
Liard et al. 11 reported conduit-related complications which required re-intervention in 11 
of 22 patients (50%) during 20 years’ follow-up after appendicovesicostomy construction. In 
other relatively large series with follow-up between 28 months and 4 years, conduit related 
re-interventions were reported in 16-55% of patients.3-10
In our series, 63.3% of the re-interventions was superficial and/or endoscopic. We assume 
that hospitalization is shorter and recovery is faster after superficial and/or endoscopic re-
interventions in comparison to more extensive re-interventions. Nowadays in our institution 
we perform endoscopic re-interventions regularly in day surgery. Due to missing data as a 
result of the retrospective study design, we were not able to report on hospitalization after 
re-interventions in our patient group. Although most series do not specifically report on the 
extent of the re-intervention, our results are in line with the literature. Welk et al.6 reported 
that 82% of the re-interventions in their study population of 67 patients with a median 
follow-up of 28 months were endoscopic or superficial. Rubenwolf et al.13 reported on 44 
children after continent urinary diversion or enterocystoplasty with a follow-up of 7.3 years. 
In 54% of the re-interventions (including stoma-related complications, ureteric stenosis, 
stone formation and adhesive small bowel ileus) only minor revisions were required. 
Like in comparable studies, cutaneous or fascial stenosis was the most prevalent complication 
which needed re-intervention in our study (in 14.8% of the patients). Reporting rates of 
comparable series vary between 6% and 39% of the patients.3-8, 10-12, 14 The second and third 
most common reasons to perform a re-intervention were stenosis at conduit-bladder level 
in 9.4%, and stomal incontinence in 6.3% of patients. This is consistent with previous series 
which report on stenosis at conduit-bladder level in 6-16%4, 6, 12 and on channel incontinence 
in 1-10% of the patients.6, 9, 12, 14 
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The outcome of dilatation of a stenotic tract was successful in three of six patients. In general 
in our hospital, dilatation is not the first choice treatment to treat a stenosis. Low success 
rates are described in literature. Suzer et al.8 reported an unsuccessful outcome of dilatation 
of a stenosis in 11 of 14 patients, Thomas et al.5 in 8 of 16 patients and McAndrew et al.7 in 
18 of 35 patients. There might be a bias in the patient selection for dilatation. Patients with 
a mild stenosis might be more likely to be treated by dilatation than people with severe 
stenosis. Due to the small number of patients who underwent dilatation and the possible 
selection bias, no conclusions can be drawn from this study to this specific topic. 
Some patients in our series used an ACE stopper to ensure the stoma open if necessary. The 
ACE stopper was not routinely prescribed. Due to the retrospective design of the study, we 
were not able to retrieve the exact number of patients using the ACE stopper. Our clinical 
experience with the ACE stopper is variable and some patients express discomfort during 
use. One report on the effectiveness of the ACE stopper in preventing stomal stenosis in the 
urinary tract has been published. Subramaniam et al.16 reported that 6/19 (32%) patients 
needed a revision after construction of a catheterizable channel without ACE stopper 
(follow-up 47 months) and no one out of 14 patients needed a revision after using an ACE 
stopper for 3-6 months postoperatively (follow-up 22 months). Some patients experienced 
minimal discomfort while using the ACE stopper. Two reports on the effectiveness of the 
ACE stopper in preventing stomal stenosis after construction of an ACE show nil stomal 
stenosis after a follow-up of 12 months17 and 8% after a mean follow-up of 2.6 years.18 
The results of these studies seem promising for prevention of stomal stenosis with an ACE 
stopper, and therefore routine use of an ACE stopper can be considered. 
In our series we found a re-intervention peak in the 1st year after conduit construction 
and yearly decreasing incidence of re-interventions thereafter. This initial peak might be 
explained by the initial postoperative healing process and patients’ unfamiliarity with 
handling the channel. We found no specifically late-onset complications or re-interventions. 
Previous studies on conduit construction also reported an initial re-intervention peak in the 
first year.5, 6, 8, 12, 14 Only two previous studies have reported particularly on the timing of re-
interventions during long-term follow-up. Leslie et al.12, reporting on 169 paediatric patients 
with a median follow-up of 5.8 years, showed declining revision rates over the years, but 
the authors recommended continuous monitoring to detect late problems. Szymanski et 
al.14 reported on an appendicovesicostomy group (median follow-up 5.7 years) and a Monti 
ileovesicostomy group (median follow-up 7.7 years) and showed a decrease in revision 
risk after 5 years, but concluded that channel complications continue over the channel’s 
lifetime. Considering results of previous studies and our results, we may conclude that late 
re-interventions are rare and that it is safe to lower the frequency of follow-up visits after 1 
year (provided the underlying diagnosis allows this). 
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With a mean follow-up of 10.1 years, mean age at conduit creation of 10.1 years and a 
mean age at the end of follow-up of 20.7 years, our study gives an overview of patients and 
their conduits developing from prepubertal children to young adults. All but one patient 
continued to use the catheterizable channel for bladder drainage. In this one exceptional 
case, the conduit could not be preserved due to ischemia of the channel and transurethral 
CIC was restarted. In only 3.9% of the study population the conduit needed to be replaced. 
These results demonstrate a good durability of the conduits during the progression of 
children to adulthood. The construction of a continent catheterizable channel is a good 
alternative for transurethral CIC in a paediatric patient group with irreversible lower urinary 
tract dysfunction. 
Thirty-five of one hundred and seven (32.7%) patients with an umbilical stoma and 6 of 21 
(28.6%) patients with a lower abdominal quadrant stoma underwent a re-intervention in 
our study population. No statistical significant difference in re-intervention rate between the 
different stomal sites was found. These results reconfirm the results of the long-term follow-
up studies of Leslie et al.12 and Szymanski et al.14 Leslie et al.12 reported no differences in 
surgical revision free survival and Szymanski et al.14 found no overall difference in subfascial 
(not stomal revision) re-intervention rate between the different stomal sites (umbilical vs. 
non-umbilical/lower quadrant). No significant relations were found between re-intervention 
rate and augmentation status, gender nor underlying diagnosis in our study population. 
A limitation of our study is the retrospective design. Missing data, (selection) bias and patient 
loss during follow-up are generally more common in retrospective studies. In addition, in 
this study we focused on re-interventions performed under general anaesthesia. We did not 
include complications which were conservatively managed or performed without general 
anaesthesia. Therefore we probably underestimated the overall complication rate. Despite 
these limitations, this study adds reliable information about the long-term outcome of 
continent catheterizable conduits in view of its large sample size and long follow-up (mean 
10.1 years). All previous studies had a shorter follow-up or a smaller study population. 
Especially in a patient group with mostly prepubertal children, monitoring the function of 
the conduit during their progression to adulthood is of interest. For patient counselling it 
is valuable to create awareness in patients and their parents about what to expect after 
reconstruction of a continent catheterizable conduit. 
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CONCLUSIONS
We present a series of 128 paediatric patients with a mean follow-up of 10.1 years after 
appendicovesicostomy creation. Our study gives an overview of patients and their 
conduits developing from prepubertal children to young adults. After construction of an 
appendicovesicostomy 32.0% of the patients needed a re-intervention. 63.3% of the re-
interventions was superficial and/or endoscopic. After an initial peak incidence of re-
interventions in the 1st year after conduit construction, the incidence of re-interventions 
decreased yearly. We conclude that creation of a continent catheterizable conduit is 
an effective and durable treatment for paediatric patients for whom transurethral CIC 
is not feasible. This information is of relevance for patient counselling and managing of 
expectations for patients and their parents. 
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PART III
A PREDICTION MODEL IN 
FUNCTIONAL UROLOGY
PART III:  

CHAPTER 7
Development of a prediction model in female 
urge urinary incontinence 
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ABSTRACT
Background: Present approach of pelvic floor disorders (PFDs) depends on the knowledge 
and preference of the caregiver/patient and might result in suboptimal patient outcomes. 
Objective: To predict the treatment outcome of urge urinary incontinence (UUI) in women. 
Design, setting and participants: Data on patient characteristics, history and investigations 
of 512 consecutive women treated for UUI in three hospitals in the Netherlands were 
retrospectively collected and evaluated as potential predictors of treatment outcome. 
Intervention: -
Outcome measurements and statistical analyses: The predicted outcome was the short-
term subjective continence outcome, defined as patient-reported continence three months 
after treatment. The outcome is categorized as cure (no urinary leakage), improvement (any 
degree of improvement of urinary leakage) and failure (no improvement or worsening of 
urinary leakage). Multivariable ordinal regression with backward stepwise selection was 
applied to analyze association between treatment benefit and patient’s characteristics. 
Discrimination ability was assessed after internal validation with c-statistic with ordinal 
outcome. 
Results and limitation: Conservative treatment was applied in 12% of the patients, 
pharmacological 62%, and invasive 26%. Subjective continence outcome was cure, 
improvement and failure in 20.3%, 48.8%, and 30.9%, respectively. Incontinence 
episodes/24h, voiding frequency during the day, subjective quantity of UI, coexistence of 
SUI, night incontinence, and bladder capacity were included in the model. Type of treatment 
interacted with predictors and resulted in individual estimates of treatment benefit. After 
internal validation the c-statistic was 0.683 for the ordinal interaction model. 
Conclusions: Six variables can be used to predict UUI treatment outcome in women. 
Further development into a complete model for the use in various PFDs and treatments 
is recommended to optimize individualized care. This model requires external validation 
before implementation.
Patient summary: Based on information of patients treated for UUI in the past, we developed 
a model that predicts the probability of improvement and cure after a UUI treatment for each 
individual female patient. In the future it could be used to personalize treatment choices. 
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INTRODUCTION
Pelvic floor disorders (PFDs) such as urinary incontinence (UI) are highly prevalent.1 
Prevalence of UI varies between 13-50% for women1 and between 1-39% for men2. UI has 
major impact on patients’ quality of life3 and has great economic impact, with high costs 
for treatment and absorbent products.1 Urge urinary incontinence (UUI), urinary leakage 
accompanied by a sudden compelling desire to pass urine4, is one of the main types of UI.1 
Treatment options vary from conservative (pelvic floor muscle training, PFMT) to invasive 
therapy like neuromodulation.5, 6 
Diagnosis and treatment decision making in patients with PFDs is a complex and often 
subjective process, depending on the knowledge and preference of the caregiver and 
patient. This might result in suboptimal patient outcomes. A prediction model could 
therefore provide support in the process of decision making. 
A prediction model calculating the probability of the type of UI the patient suffers and at 
the same time providing the optimal choice of treatment does not yet exist. Such a model 
will, if implemented into daily clinical practice contribute to individualised care. A successful 
multivariable prediction model is the Prostate Cancer Risk Calculator.7 This multiple 
externally validated prediction tool has shown to be able to reduce unnecessary testing in 
men with low risk of harbouring a life threatening prostate cancer.7, 8 
Such tools, combining diagnostics and prognostics are currently lacking in the field of PFDs. 
As a first step we aim to develop a multivariable model to predict the effect on continence 
outcome of different UUI treatments. It could aid in shared decision making when choosing 
UUI treatment in female patients. 
PATIENTS AND METHODS
Study design and subjects
The study was conducted at the departments of urology in one academic hospital (Erasmus 
MC) and two non-academic hospitals (Amphia Hospital and Haven Hospital) in the 
Netherlands. Data of female adult consecutive patients treated for UUI from 2010 (Erasmus 
MC), from 2013 (Amphia Hospital), or from 2015 (Haven Hospital) to 2016 were retrospectively 
included. These starting years coincided with the institutions’ implementation of electronic 
patient files. Eligible patients were identified based on ‘diagnosis treatment combination 
codes’ used for reimbursement of health care costs in the Netherlands. Only data on the 
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first UUI treatment during the inclusion period were evaluated based on the intention-to-
treat principle. Patients with bladder stones, bladder cancer, urinary tract infections, urinary 
catheters, (congenital) anatomical abnormalities of the urinary tract, neuro-urological 
dysfunction, symptomatic pelvic organ prolapse and pregnant women were excluded. The 
medical ethics review board of the Erasmus MC reviewed the study protocol (MEC-2016-
103). All data were collected from the electronic patient files. For quality control, 5% of all 
data entered into the study database was cross-checked with the patient file (JS, TN, IG). 
Predicted outcome parameter
The predicted outcome parameter was the short-term subjective continence outcome 
reported three months after initiation of UUI treatment, and was categorized as cure (no 
urinary leakage), improvement (any degree of improvement of urinary leakage), or failure 
(no improvement or worsening of urinary leakage). A time range between one week and six 
months was accepted depending on the evaluated treatment. An outcome of percutaneous 
needle evaluation after one week was considered acceptable while, e.g., an outcome one 
week after initiation of PFMT was not.
Predictive variables
Table 1 shows the variables that were considered potential predictors for treatment 
outcome. Other previous invasive treatments with influence on the continence status 
included therapies such as a hysterectomy or prolapse surgery. For variables derived from 
bladder diaries, the mean values for two days were used if available. Detrusor overactivity 
(DO) was defined as any involuntary detrusor muscle contraction during filling cystometry.4 
The cystometric bladder capacity was defined as maximum filling during urodynamic studies 
(UDS). Cough-stress-tests were considered positive in case of any urinary leakage during 
coughing or Valsalva maneuver. 
The type of UUI treatment was categorized as conservative, pharmacological or invasive. 
Conservative treatment was defined as any treatment for UUI without the use of invasive 
or drug therapy, such as PFMT. Invasive treatment was defined as any treatment involving 
incision or puncture of the skin, such as sacral neuromodulation (SNM) or Botulinum toxin-A 
(BTX-A) injections in the detrusor muscle. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
PREDICTION MODEL IN UUI
113
7
Table 1. Baseline patient characteristics – evaluated as potential predictors
Characteristics
Age (y)
Missing
60.8 (50.0-70.9)
0
Length
Missing
1.65 (1.60-1.70)
124 (24)
Weight (kg)
Missing
75.0 (66.0-90.0)
125 (24)
BMI, kg/m²
Missing 
28.0 (24.5-32.1)
127 (25)
Patient history
Coexistence of SUI 
   Yes 270 (52)
   No
   Missing
196 (38)
46 (9)
In case of coexistence of SUI:  predominant type of UI
   UUI 211 (41)
   SUI 19 (4)
   Equal
   No coexistence
   Missing
3 (1)
196 (38)
83 (16)
Voiding frequency/24h 
   Missing
13 (10-17)
226 (44)
Voiding frequency during the day 
   Missing
10 (8-13)
209 (41)
Voiding frequency during the night 
   Missing
3 (1-4)
193 (38)
Incontinence pad use/24h 
   Missing 
3 (2-5)
121 (24)
UI during night 
   Yes 142 (28)
   No
   Missing
82 (16)
288 (56)
Vaginal deliveries
   0
   1
   More than 1
   Missing
90 (18)
68 (13)
273 (53)
81 (16)
Episiotomies or spontaneous lacerations (during vaginal deliveries) 
   0
   1
  More than 1
  Missing
128 (25)
83 (16)
66 (13)
235 (46)
Comorbidities
DM
   Yes 69 (13)
   No
   Missing
443 (87)
0 
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Cardiovascular disease
   Yes 225 (44)
   No
   Missing
287 (56)
0
COPD
   Yes 34 (7)
   No
   Missing
476 (93)
2 (0)
Psychiatric disorders and/or sexual abuse
   Yes 96 (19)
   No
   Missing
69 (13)
347 (68)
Previous treatments
Previous treatments for UUI
   None 183 (36)
   Conservative 114 (22)
   Pharmacological 152 (30)
   Invasive
   Missing
63 (12)
0
Previous surgical treatments for SUI
   Yes   
   No
   Missing
73 (14)
438 (86)
1 (0)
Previous other invasive therapies with 
         influence on continence status
   Yes 184 (36)
   No
   Missing
326 (64)
1 (0)
Current treatment
Type of UUI treatment
   Conservative
   Pharmacological
   Invasive
   Missing
64 (12)
317 (62)
131 (26)
0
Bladder diary
Number of UI episodes/24h 
   Missing
5 (2-8)
220 (43)
Subjective quantity of UI 
   None 20 (4)
   Drops 62 (12)
   A splash 103 (20)
   A lot 
   Missing
156 (31)
171 (33)
Number of incontinence pad use/24h 
   Missing
3 (2-5)
121 (24)
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Voiding frequency/24h 
   Missing
11 (9-114)
118 (23)
Voiding frequency during the day
   Missing
9 (7-12)
118 (23)
Voiding frequency during the night
   Missing
2 (1-3)
118 (23)
Maximum portion of urine 
   Missing
350 (250-500)
135 (26)
Mean volume of a portion of urine 
   Missing
166 (121-210)
135 (26)
Total voided volume/24h 
   Missing
1800 (1273-2363)
138 (27)
Fluid intake/24h 
   Missing
1725 (1350-2150)
281 (55)
Urodynamic study
DO 
   Yes 169 (33)
   No
   Missing
93 (18)
250 (49)
In case of DO: (n = 169) 
DO from mL filling
   Missing
166 (80-268)
14 (8)
In case of DO: (n = 169) 
leakage during DO
   Yes 93 (55)
   No
   Missing
66 (39)
10 (6)
Bladder capacity 
   Missing
350 (210-480)
253 (49)
Cough-stress test 
   Positive 64 (12)
   Negative 
   Missing
187 (37)
261 (51)
Other investigations
Cough-stress test (separate test)
   Positive 96 (19)
   Negative
   Missing
158 (31)
258 (50)
BD, bladder diary; BMI, Body Mass Index; COPD, chronic obstructive pulmonary disease; DM, diabetes 
mellitus; DO, detrusoroveractivity, IQR, inter quartile range; kg, kilogram; mL, milliliter; PH, Patient 
History; SUI, stress urinary incontinence; UI, urinary incontinence; UUI, urge urinary incontinence; 
y, year. Data are displayed as n (%) or median (interquartile range). Numbers do not add up to 512 
patients due to missing data. 
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Analyses
Descriptive statistics were used to summarize data. For all variables except age, diabetes 
mellitus (DM), cardiovascular disease, and type of UUI treatment, data were missing. These 
missing data (1%-68%) were imputed using multiple imputation with the chained equations.9 
Due to high percentage of missing values we did not include the variable ‘in case of DO: from 
mL filling’ and ‘leakage during DO’ in further analyses.
Ordinal logistic regression was used to evaluate the association between each prognostic 
factor and the three outcomes: dry, improvement, failure. As a first step, predictors 
were entered into univariate regression model, taking into account the multiple imputed 
datasets. Significant predictors form the univariate regression were entered into the ordinal 
regression model with a backward stepwise selection procedure using the Wald selection 
criterion (p<0.157).10 Subsequently, the main effect model was augmented with interaction 
of the three treatment options. Statistical significance of interactions in main model was 
quantified by the p-value of the overall likelihood ratio test statistic.11
The overall model performance predicting the absolute treatment benefit was assessed with 
the ordinal c-statistic.12 The model was internally validated using bootstrapping with 200 
samples. Predictor effects were shrunken using the calibration slope at internal validation 
as heuristic shrinkage factor. Due to the treatment interaction, the predictive value of a 
single predictor cannot easily be interpreted. The predictive value i.e. logit is visualized with 
a Logit plot for every predictor. All statistical analyses were performed using R version 3.4.2 
(R Foundation, Vienna, Austria) with package ‘rms’ and mice.9, 13
RESULTS
Based on ‘diagnosis treatment combination codes’, 1395 consecutive female adult patients 
with UUI were identified. Twenty-five percent of these patients was not treated (for UUI) or 
treatment was not adjusted and 33% was excluded based on one or more of the exclusion 
criteria. In total, 598 female patients met the inclusion criteria. Data of 86/598 (14.4%) were 
excluded because no short-term subjective continence outcome could be determined from 
the patient file. Of the 512 remaining patients, 235 (45.9%) were recruited from the Erasmus 
MC, 204 (39.8%) from the Amphia Hospital, and 73 (14.3%) from the Haven Hospital. 
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Table 2. Subjective continence outcome categorized by treatment groups 
Conservative
(N = 64)
Pharmacological
(N = 317)
Invasive
(N = 131)
Total
Cure 7 (10.9%) 51 (16.1%) 46 (35.1%) 104 (20.3%)
Improvement 30 (46.9%) 165 (52.0%) 55 (42.0%) 250 (48.8%)
Failure 27 (42.2%) 101 (31.9%) 30 (22.9%) 158 (30.9%)
In univariate analyses, number of UI episodes/24h, voiding frequency during the day based 
on patient history, coexistence of SUI based on patient history, predominant type of UI, UI 
during night, bladder capacity and subjective quantity of UI were found significant (Table 3). 
Predominant type of UI was manually removed, due to limited cases in the conservative and 
invasive treatment groups. All other predictors were still individually significant after the 
backward selection procedure. Addition of treatment interaction resulted in an increase in 
predictive capability (LR ratio test: Chisq: 39.5 p < 0.001 with 14 degrees of freedom). The 
ordinal c-statistic for the complete model was 0.710 and after internal validation 0.683. 
Figure 1, based on the average patient in our cohort, displays the predictors on the X-as 
and the predictive ability (Logit) on the Y-axis, where a higher Logit indicates a higher 
probability of improvement or cure. In general, a larger bladder capacity, higher voiding 
frequency during the day, and UI during the night increase the probability of a successful 
treatment while the subjective quantity of UI ranked as ‘a lot’, the coexistence of SUI and 
an increased number of UI episodes/24h decrease the probability of a successful treatment. 
The predicted outcome of UUI treatment for the several factors is also illustrated in two 
fictive patients in Table 4. 
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Figure 1. Predictive value of the six predictors with respect to improvement or cure of incontinence 
in the average patient (defined as Coexistence of SUI (yes), Voiding frequency during the day (10), UI 
during night (yes), Number of UI episodes/24h (5), Subjective quantity of UI (a lot), Bladder Capacity 
(350)) visualized with Logit plots, stratified to treatment option. A higher Logit indicates a higher 
probability of improvement or cure.
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Table 3. Univariate analysis 
Variable Odd Ratio (95% CI)
Characteristics
Age 0.92 (0.74-1.14)
Length 0.94 (0.72-1.22)
Weight 1.10 (0.87-1.39)
BMI 1.12 (0.88-1.43)
Patient history
Coexistence of SUI (Yes) 0.69 (0.50-0.96)*
In case of coexistence of SUI: 
predominant type of UI (SUI vs. UUI & no coexistence)
0.24 (0.09-0.62)*
Voiding frequency/24h 1.15 (0.92-1.43)
Voiding frequency during the day 1.18 (0.97-1.43)*
Voiding frequency during the night 0.89 (0.70-1.14)
Incontinence pad use/24h 1.00 (0.84-1.17)
UI during night (Yes) 1.44 (0.89-2.32)*
Vaginal deliveries (1 or more vs. No) 1.08 (0.64-1.82)
Episiotomies or spontaneous lacerations (1 or more vs. No) 0.91 (0.58-1.44)
Comorbidities
Comorbidity, any (Yes) 0.96 (0.69-1.33)
Sexual and/or physical abuse (Yes) 1.54 (0.68-3.47)
Psychiatric diagnosis (Yes) 1.23 (0.61-2.49)
Previous treatments
Previous treatments for UUI 
   None Ref
   Conservative 0.83 (0.53-1.29)
   Pharmacological 0.77 (0.51-1.15)
   Invasive 1.20 (0.70-2.07)
Previous surgical treatments for SUI (Yes) 1.31 (0.81-2.11)
Previous other invasive therapies with influence on continence status (Yes) 1.17 (0.83-1.65)
Current treatment
   Conservative Ref
   Pharmacological 1.53 (0.92-2.53)*
   Invasive 3.30 (1.85-5.87)*
Bladder diary
Number of UI episodes/24h 0.77 (0.59-0.99)*
Subjective quantity of UI (a lot vs. a little) 0.70 (0.49-0.99)* 
Number of incontinence pad use/24h 0.92 (0.78-1.09)
Voiding frequency/24h 0.96 (0.78-1.18)
Voiding frequency during the day 1.01 (0.81-1.26)
Voiding frequency during the night 0.87 (0.73-1.06)
Maximum portion of urine 0.92 (0.66-1.29)
Mean volume of a portion of urine 0.91 (0.73-1.15)
Total voided volume/24h 1.03 (0.66-1.60)
Fluid intake/24h 0.99 (0.77-1.26)
Urodynamic study
DO (Yes) 0.90 (0.58-1.38)
DO from mL filling 0.86 (0.54-1.35)
leakage during DO 0.84 (0.46-1.51)
Bladder capacity 1.41 (1.10-1.83)*
Cough-stress test (Positive) 1.37 (0.93-2.04)
Other investigations
Cough-stress test (Positive) 1.10 (0.58-2.08)
Odds ratio (OR) for continuous variables are calculated between first and third quartile. OR>1 indicates improved 
cure rate. BMI, Body Mass Index; SUI, stress urinary incontinence; UI, urinary incontinence; UUI, urge urinary 
incontinence. Comorbidity is positive in presence of cardiovascular disease, chronic obstructive pulmonary disease 
or diabetes mellitus disease. * Significant with p<0.157
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Table 4. The predicted short-term subjective continence outcome for two fictive patients based on 
our multivariate prediction model
A) Female patient, six urinary incontinence episode/24h, 11 voiding frequency during the 
day, coexistence of SUI, no extensive subjective quantity of UI, UI during the night, and a 
bladder capacity of 400cc
Patient information – model predictors
Predicted short-term subjective 
continence outcome
Type of treatment: Conservative Probability of CURE: 12%
Probability of IMPROVEMENT: 52%
Probability of FAILURE: 36%
Type of treatment: Pharmacological Probability of CURE: 20%
Probability of IMPROVEMENT: 56%
Probability of FAILURE: 24%
Type of treatment: Invasive Probability of CURE: 38%
Probability of IMPROVEMENT: 51%
Probability of FAILURE: 11%
B) Female patient, 15 urinary incontinence episode/24h, 11 voiding frequency during the 
day, coexistence of SUI, extensive subjective quantity of UI, no UI during the night, and a 
bladder capacity of 300cc
Patient information – model predictors
Predicted short-term subjective 
continence outcome
Type of treatment: Conservative Probability of CURE: 3%
Probability of IMPROVEMENT: 27%
Probability of FAILURE: 70%
Type of treatment: Pharmacological Probability of CURE: 6%
Probability of IMPROVEMENT: 39%
Probability of FAILURE: 55%
Type of treatment: Invasive Probability of CURE: 8%
Probability of IMPROVEMENT: 45%
Probability of FAILURE: 47%
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DISCUSSION
We developed a multivariable model to predict the effect of UUI treatment in female 
patients. The model, providing estimates of treatment outcome, includes information from 
bladder diaries, patient history, and urodynamic studies and might, after being externally 
validated, be a promising aid in shared decision making for the use in daily practice. 
Other prediction models in the field of PFDs and functional urology are, for example, a model 
that predicts the future risk of PFDs.14 It provides the opportunity of prevention during 
pregnancy in high-risk patients. More specific to our area of work, Darekar et al.15 reported 
on the development of a model to predict the outcome of UUI treatment with fesoterodine. 
In both our study and that of Darekar et al.15 a lower number of UI episodes/24h was found 
to be a positive predictor for being dry after treatment. Herschorn et al.16 also acknowledged 
this variable as a predictor for being dry after antimuscarinic treatment. Although using other 
outcome parameters (reduction in UI episodes or symptoms), Yazdany et al.17 and Richter 
et al.18 also found associations between the number of UI episodes/24h and outcome of 
UUI therapies (BTX-A and SNM). Hence, the number of UI episodes can be interpreted as a 
measure of the severity of incontinence. Furthermore, the quantity of UI can be interpreted 
as a measure of the severity of incontinence. It is shown in this study that the quantity of 
UI ranked as ‘a lot’ rather than ‘none or a little’ decreases the probability of a successful 
outcome. We can conclude from these two predictors that, in general, patients with more 
severe UI are more difficult to treat. 
The presence of UUI is often a symptom of the overactive bladder syndrome, defined as a 
complex of symptoms including urinary urgency, with or without UUI, usually with voiding 
frequency and nycturia.4 Patients with this syndrome often present clinically with high 
voiding frequency and small portions of urine. We had expected that a higher probability of 
cure after UUI treatment, would be associated with a lower voiding frequency and a higher 
bladder capacity, reflecting a lower severity overactive bladder syndrome. For example, a 
higher therapeutic efficacy of BTX-A was described to be associated with lower baseline 
score of overactive bladder symptoms.19 In line with this, in our study we found that a 
positive treatment outcome was associated with a higher bladder capacity. Contrary and 
unexpectedly, we found that a positive treatment outcome was associated with a higher 
voiding frequency during the day. No explanation could be found for this result. Future 
research should focus on this topic.
The coexistence of SUI and UUI is associated with worse outcomes in incontinence 
treatments such as PFMT and surgical treatments for SUI.20 In our study the coexistence of 
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SUI (based on patient history) was found to be a predicting factor for failure of treatments, 
especially in patients with predominant SUI. A possible explanation is that by treating the 
UUI component, the SUI component remains untreated and might even worsen due to the 
increased bladder capacity after UUI treatment. 
Additionally, we found that patients who experienced UI during the night had a higher 
probability of cure and improvement. The presence of UI during the night might be 
representative for pure UUI and therefore better outcomes of UUI treatment. 
The type of treatment as interaction improved the prediction of individual treatment benefit 
in terms of the subjective continence outcome. Our study showed that that conservative, 
pharmacological and invasive therapy have increasing cure rates, which is in line with the 
previous published literature.5, 6, 21, 22 
 
Variables concerning DO derived from urodynamics were not found to be predictive for the 
outcome of UUI treatment. This is in concordance with findings from a systematic review 
of Rachaneni et al.23 that concluded that the presence of DO seems not to influence the 
effectiveness of invasive UUI treatments. 
In the present study, comorbidities and previous treatments were not found as predictors 
for outcome of treatment. The scarce evidence on this topic is contradictory. While Darekar 
et al.15 also did not find prior pharmacological UUI treatment and DM as predictors for 
pharmacological treatment outcome, Herschorn et al.16 did find previous UUI treatments to 
be predictive. Khan et al.24 found that depression or anxiety might influence the outcome of 
PFMT; Marcelissen et al.25 found that psychological factors could not predict success in SNM. 
If future research confirms our findings, this is interesting information for clinical decision 
making. In current clinical practice, comorbidities and previous treatments are often a 
reason to refrain from further (invasive) treatments in these patients to avoid burdensome 
procedures. 
Other bladder diary and patient history derived parameters, such as the number of 
incontinence pad use/24h, portions of urine and voiding frequency during the night were 
not found as predictors. We had expected that especially pad use would have predictive 
value, based on the idea that this reflects the severity of UUI. On the other hand, Dylewski 
et al.26 showed that the number of pad use is not associated with the quantity of urine lost. 
The strength of present study lies in the model that predicts the improvement or cure not 
only of a single treatment, but of three UUI treatment outcomes based on multicenter data. 
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This makes it possible to compare between the three treatment options and aids in shared 
decision making. This study represents the first step, of developing a comprehensive set of 
prediction models for PFDs. However, several limitations of our study need to be addressed. 
First, confounding could have been introduced due to the retrospective study design and 
treatment decisions being based on the judgement of the treating physician. The interaction 
modeling strategy to explore treatment benefit would be most optimal in a randomized 
(collaborative) setting with increased sample size and prospectively collected data.27 
Second, due to small numbers for specific treatments (e.g. BTX-A, SNM), treatment benefit 
could only be categorized as conservative, pharmacological or invasive. It might well be that 
the predicting factors differ per specific treatment. When more patient data have become 
available, sub-analyses per specific treatment could be performed. Third, only internal 
validation could be performed and external validation is still required to confirm the model’s 
performance.28 Fourth, there was a high number of missing data, which were imputated, 
however, we cannot rule out that variables entering the main model were selected or 
rejected based on chance. Finally, the choice of the outcome parameter ‘subjective 
continence outcome’ could be criticized. We chose however to include this outcome 
parameter, since it is commonly used in clinical care. Disadvantages are the subjectivity of 
the measure, the lack of standardization, and the wide range of patients categorized under 
‘improvement’. Ideally a validated questionnaire, with a previously determined minimally 
important change, should serve as an outcome parameter. In contrast, from a clinical 
point of view, treatment for UI is based on patient-reporting and the subjective continence 
outcome is easy recognizable for patients in shared decision making. 
CONCLUSION
We identified six independent predictors for the short-term subjective continence outcome 
of UUI treatments in women and developed a multivariable prognostic prediction model. 
The model has the potential to be used as an aid in decision making for patients and 
physicians in the future. This study represents a first step in developing prediction models 
for use in various pelvic floor disorders. Before implementation of the prediction model in 
practice external validation is required.
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Take home message
We present a prognostic prediction model for short-term subjective continence outcome of 
urge urinary incontinence treatments in women with the potential to be used as an aid in 
decision making for patients and physicians in the future.
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CHAPTER 8
General discussion
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In this general discussion, the main findings of the studies are presented and put in the 
context of the present literature. The fundamental research questions of this thesis are 
answered: 
1) Can we lay the foundations to construct a complete diagnostic and prognostic 
prediction model in pelvic floor disorders (PFDs) in the future?
2) Can we construct the first part of this prediction model, a prognostic model that 
predicts the outcome of urge urinary incontinence (UUI) treatment?
Furthermore, the potential implications for research and clinical practice (for the future) are 
discussed. Finally, the overall conclusion of this thesis is given. 
STANDARDIZATION
In chapter 2 a systematic review was described, which summarized all outcome parameters 
and definitions of cure used to describe outcome of surgical treatments for stress urinary 
incontinence (SUI) in neuro-urological (NU) patients. A great heterogeneity in outcome 
reporting was found: sixteen different outcome parameters and nine different definitions 
of cure or success were used in the seventeen included studies. The most commonly used 
outcome parameter was patient-reported pad use, reported during an interview. Only three 
studies used a standardized patient-reported outcome measure (PROM). This heterogeneity 
makes it difficult to compare outcomes of different studies and therapies. This systematic 
review was performed to delineate the extent of this problem. 
The heterogeneity in outcome reporting in healthcare was earlier described for outcome 
reporting in PFDs of non-neurological origin.1, 2 Outcome reporting in the specific group of 
NU patients did not differ from that in other patient groups according to the heterogeneity 
found in our study (chapter 2). As a consequence of the use of various outcome parameters 
and definitions of cure it is difficult to validly compare outcomes of studies or interventions. 
For example, when considering two treatment options: a study on the one presents 
outcomes by the number of patients who report to be satisfied after treatment, while a 
study on the other describes outcome by reporting the number of patients whose urinary 
incontinence (UI) episodes were reduced by 50% or more after treatment. It is impossible 
to compare, based on this information, the differences in efficacy between the two 
treatment options. Furthermore, subjective and objective outcome parameters, PROMs and 
traditional outcome measures are used interchangeably within and between studies. An 
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important question is: what is most appropriate outcome parameter to describe efficacy of 
a treatment? This issue concerns both the research field and clinical practice. 
Systematic reviews on treatment efficacy are aimed to build robust evidence by combining 
outcomes of different studies. Guidelines are often based on the outcomes of systematic 
reviews. When outcome parameters and definitions of cure in included studies of systematic 
reviews differ, meta-analyses cannot be performed and outcomes on efficacy of different 
therapies are inconclusive. 
The COMET-initiative tries to reach consensus among different healthcare specialties on 
outcome parameters for research purposes.3 The intention is to develop core outcome sets, 
standardized sets of outcomes, per specific healthcare field for use in research. Important 
issues here are described as: identifying the scope for the outcomes, inventorying the 
existing knowledge on outcome sets in the specific areas, the involvement of different 
key stakeholders such as patients, clinicians, and researchers, and methods of reaching 
consensus.4 Reviews of previous trials can reveal need for a core outcome set and identify 
a potential list of outcomes.4 For this purpose, our systematic review (chapter 2) is an 
appropriate review; it describes the heterogeneity in outcome reporting in the specific field 
of SUI in NU patients and it summarizes all used outcome parameters and definitions of cure 
or success. Therefore, it might lie on the basis of a future consensus on this topic. 
The use of outcome parameters and definitions of cure is a complex issue specifically in 
the field of PFDs and functional urology, because it is not immediately clear what outcome 
parameter should be used for this patient group. In other areas of health care such as 
cancer or cardiovascular disease it is often more obvious; e.g., survival as a clear outcome. 
Furthermore, the patient’s quality of life and subjective perception or satisfaction are the 
most important goals of therapy in functional urology. Therefore, it would also be very 
important to have patients participate in the discussion on what outcome parameters to 
use. It is difficult, however, to measure a patient’s subjective perception, such as the impact 
of disease on the quality of life. It is often based on the patient history and hard to quantify. 
This is the reason why PROMs have been introduced. Surprisingly, in our systematic review 
(chapter 2) only three of the seventeen studies used a PROM as an outcome measure. This 
shows that PROMs are not yet fully implemented into the research field of PFDs. The use of 
PROMs in daily healthcare practice is virtually absent.
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PATIENT REPORTED OUTCOME MEASURES (PROMS)
For evaluation of PFDs such as UI, which can have major impact on the quality of life5, 
PROMs are very important. When only using objective outcome parameters, the impact 
of symptoms on the patient’s life is often not taken into account. PROMs can make the 
subjective perception of a patients measurable and available in a standardized way. PROMs 
can be valuable at different points in the care trajectory. They can be used as a diagnostic 
tool or as a baseline measurement to assess a patient’s perception and impact of symptoms 
on his or her daily life. The impact of symptoms on the quality of life measured by PROMs 
can also guide the decision whether or not to start (invasive) treatments and thereby 
enhance patient-centered care. In addition, PROMs may serve as an outcome measure for 
treatment evaluation in a research setting, and also for this purpose in clinical practice. 
Symptom burden or health-related quality of life over time can be measured. 
The implementation of PROMs into standard care showed to increase patient satisfaction 
with health care6 and to improve diagnostic procedures and communication between 
physician and patient.7 Due to improved communication and physicians being informed about 
patient’s perception, it is imaginable that the use of PROMs could also influence treatment 
decisions and eventually (treatment) outcome, but this is not yet clear. Recognition of the 
importance of implementation of PROMs is upcoming, and the use of PROMs has already 
been recommended by several national and international guidelines on PFDs.8-11 
At present, both the availability of PROMs and the general implementation of the PROMs 
into research and clinical care are challenging issues. Several PROMs for the use in PFDs 
have recently been translated into Dutch and validated for use in the Netherlands.12-16 There 
is still a lack of validated PROMs for assessment of patients’ perception in NU patients in the 
Netherlands. For example, a PROM for the use in patients with bowel complaints and fecal 
incontinence such as the neurogenic bowel dysfunction score17 and a sexual PROM such as 
the MSISQ-1518, 19 for the use in neurogenic PFDs patients are not yet available in a Dutch 
validated version. Until recently, a PROM focusing on the quality of life in NU patients with 
urinary symptoms was also not available. 
To improve the availability of PROMs for the use in NU patients in the Netherlands, the 
SF-Qualiveen was translated into Dutch and validated in the Netherlands. The Qualiveen 
is a measure that consists of 30 questions to assess NU patients’ urinary-specific quality 
of life.20, 21 It was originally developed for spinal cord injury (SCI) patients and later on also 
validated for the use in multiple sclerosis (MS) patients. The SF-Qualiveen is a short version 
of the Qualiveen.22 Both the English Qualiveen and the SF-Qualiveen proved to have good 
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measurement properties.20-22 In Dutch the Qualiveen, SF-Qualiveen, or a similar PROM has 
not been available. In chapters 3 and 4 the translation and validation process of the SF-
Qualiveen into Dutch for the use in MS and SCI patients in the Netherlands was described. 
We chose to translate and validate the SF-Qualiveen, the short version questionnaire, 
for the ease-of-use of patients and physicians. In general, after translation of a validated 
questionnaire into another language, validation of that language version is necessary to 
account for any cross-cultural differences. The proposed guidelines for translation and 
validation were adhered to in our study.23 The Dutch SF-Qualiveen scores correlated with 
the scores on the reference standard, UDI-614, that showed good criterion validity. Construct 
validity was confirmed by predefined hypotheses that were met: patient scores were 
significantly higher than control scores and patients with higher scores on the SF-Qualiveen 
reported more bother from urinary symptoms. By comparing the SF-Qualiveen scores 
between baseline and 1-2 weeks later, the Dutch SF-Qualiveen showed good reproducibility. 
Additionally, it was found that the different items of the SF-Qualiveen were measuring the 
same concept, i.e. items were correlated, which confirmed good internal consistency. As an 
unexpected observation, the domains that were present in the Qualiveen were not found 
in the short version SF-Qualiveen and therefore we recommend to only use the entire SF-
Qualiveen and not the separate domains. All outcomes were found comparable for the use 
in MS (chapter 3) and SCI (chapter 4) patients. These studies confirm that the SF-Qualiveen 
can be validly used in the Netherlands.
After making PROMs available for use, their structural implementation into clinical care is 
another challenge. Black et al.24 speculated on how to implement PROMs into clinical care. 
The use of new technologies to provide PROMs (web based entry systems or apps) could 
make implementation easier. On the other hand, physicians and patients could find it very 
time-consuming to complete and interpret the PROMs. Routine use could be supported by 
making PROMs short, easy to understand and with scores that can easily be interpreted. To 
increase the ease of interpretation of PROMs, it can be useful to determine cut-off values 
for PROMs, e.g., to distinguish a ‘normal score’ from an ‘abnormal score’. An example is 
the International Prostate Symptom Score, IPSS, a symptom assessment tool for patients 
with benign prostate hypertrophy25 that categorizes scores into mild, moderate and severe 
complaints. Additionally, determination of the minimally important change, defined as ‘the 
minimal change in score that patients perceive as beneficial and which would mandate, 
in the absence of troublesome side effects and excessive cost, a change in the patient’s 
management26 can increase the ease of interpretation of PROM scores.
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THERAPY OUTCOMES
In part II of this thesis, interventional therapies to regain urinary continence are evaluated 
using more traditional outcome measures. Outcomes derived from urodynamics, pad tests, 
bladder diaries, and cough-stress tests can be seen as traditional outcome measures, and 
these differ from PROMs in that they do not specifically take the perspective of the patient 
into account. 
UI remains a common complication after radical prostatectomy.27 The artificial urinary 
sphincter is still the gold standard treatment for moderate to severe post prostatectomy 
SUI, but minimal invasive techniques such as ProACT (Prostate Adjustable Continence 
Therapy), have become more available and earned their place in the treatment of male 
SUI.28 Chapter 5 focuses on the mechanism of action of the ProACT in men with UI after 
radical prostatectomy. The ProACT is a system that comprises two volume adjustable 
balloons that are placed paraurethrally. These balloons are attached to a port inserted 
into the scrotum. Via this port the balloons can be separately adjusted until continence is 
achieved.29 The maximum urethral closure pressure (MUCP) decreases after prostatectomy, 
probably as a consequence of the loss of forces previously generated by the prostate 
and urethral sphincter. In men who regain continence after prostatectomy, MUCP values 
are higher compared to men who remain incontinent.30 The hypothesis that the ProACT 
induces changes of the static urethral pressure is researched in chapter 5. Included patients 
underwent a urethral pressure profilometry before and after ProACT insertion. A statistically 
significant increase in urethral pressure was found in the patients with a successful clinical 
outcome (defined as the use of no or one precautionary incontinence pad per day) when 
comparing the pre- versus the postoperative MUCP. In the unsuccessful outcome group 
this increase was not found. Furthermore, a statistically significant difference was found 
between the increase in MUCP in the successful versus the unsuccessful outcome groups. 
These findings suggest that increased urethral pressure contributes to achieving continence 
and give insight to the mechanism of action of the ProACT. This knowledge can also be used 
in the development of future continence devices. 
In chapter 6 we describe the long-term outcomes of appendicovesicostomy (AVS) surgery in 
children. In case of irreversible lower urinary tract dysfunction and the inability to perform 
clean intermittent catheterization through the urethra, constructing an AVS can be a 
solution for catheterization of the bladder and improvement of continence. Literature on 
the long-term follow-up after AVS placement, especially with a focus on the durability of 
treatment, complications and re-interventions, is scarce. In this study we found that, after a 
mean follow-up of 10 years, all but one of 128 included patients continued to use their AVS 
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for bladder drainage. Roughly one third of the patients needed a re-intervention during this 
period. No variables were identified that could predict the need for re-intervention. 
Utomo et al.31 searched for urodynamic predictors for the success or failure of a ProACT 
therapy and found that a longer duration of UI, more severe UI and a smaller cystometric 
bladder capacity were predictors for failure. Although the study described in chapter 5 was 
not designed to find predictors for treatment outcome, it is imaginable that in the future 
urethral pressure profilometry could be used in predicting successful outcome as well. In 
chapter 6 various variables were evaluated as potential predictors for the need for a re-
intervention, but none was found to be a significant predictor. 
The identification of variables that predict the outcome of treatment can help to identify 
patients that will or will not respond to a certain treatment. If beforehand it is likely that 
outcome of a specific therapy will not be successful in an individual patient, another 
treatment could be initiated as first treatment. To accurately predict treatment outcome, 
different predictors should be combined in a multivariate model. 
A PREDICTION MODEL IN PELVIC FLOOR DISORDERS
In part III, chapter 7, the development is described of a multivariate prognostic model that 
aimed at prediction of the outcome of UUI treatment in female patients based on patient 
characteristics, patient history and investigations. The model consists of six predictors 
(number of UI episodes/24h, voiding frequency during the day, subjective quantity of UI, 
coexistence of SUI, UI during the night, and bladder capacity) and has the potential to be 
implemented into clinical care after external validation in the future. Although our model 
has a moderate predictive power and some limitations, it shows great promise to be able to 
develop a model in this patient group to predict the outcome of treatment in PFDs.
In this thesis, we are working towards the development of a comprehensive prediction 
model in PFDs in the future: a combined diagnostic and prognostic (treatment outcome) 
prediction model. The diagnostic part of the model can predict the risk of disease in present 
time and the prognostic part can predict both treatment outcome and the risk of disease 
development in the future. Our focus is first on the prognostic treatment outcome part 
of the model. Important requirements for the development of such a complete prediction 
model and its potential implications are discussed below. 
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Requirements for developing a prediction model
Preferably, a prediction model is based on data of large cohorts representative for the 
patient population and followed prospectively. A prospective study design will achieve 
high quality data with missing data kept to a minimum. Another optional study design is 
a randomised trial, which will minimize the bias of treatment indication.32 Variables that 
predict the outcome of interest should be selected. Predictors are preferably standardized, 
clearly defined and reproducible. As a single predictor can often not give an adequate 
prognosis, different predictors should be combined in a multivariable prediction model. This 
strategy will probably lead to the best prediction.32 Furthermore, to build a prognostic model 
predicting treatment outcomes, the outcomes of different therapies need to be available. 
The predicted outcome measures should be standardized, clearly defined, available for 
use and, moreover, clinically relevant for patients, with the perception of the patient taken 
into account.32 When developing a prediction model in PFDs, several types of health care 
practitioners should preferably be involved, such as urologists, gynaecologists, rehabilitation 
specialists, general practitioners, surgeons, gastroenterologists, physiotherapists and nurses, 
because the treatment of PFDs is multidisciplinary. Moreover, all other participants in the 
health care chain, like patients, health insurers, relevant governmental bodies and industry 
representatives, should also be involved.
Potential implications and impact of prediction models 
Physicians can use a prediction model in clinical care as an aid in decision making in addition 
to the physician’s expertise and guidelines.32 A diagnostic prediction model can give guidance 
in the choice of referral of a patient or in the choice to perform further investigations. 
The prognostic treatment outcome model can give an accurate estimate of outcome 
probabilities and can help to select the optimal treatment for the individual patient. Ideally, 
the possibility of treatment response or non-response is established beforehand so that 
every single patient will get the optimal personal management. In spite of the recent spate 
of publications about multivariate prediction models in health care, studies that investigate 
the actual impact of using a prediction model in clinical practice are scarce.33 In the field 
of cardiovascular disease it is shown that cardiovascular prognostic risk assessments can 
change physician’s decision making, e.g., by prescription of medication in high-risk patients, 
and that it can influence patient’s outcomes in a positive way.34
Furthermore, a prognostic model gives accurate probabilities on (treatment) outcome 
which can be used to manage patients’ expectations. This information can be used in 
shared decision making, which encounters a partnership between patient and health care 
professional in making healthcare choices.35 One of the key elements in shared decision 
making is adequately informing the patient on expected (treatment) outcomes. 
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Multivariable prediction models can also be used to investigate the added predictive value 
of a single variable, e.g., an additional investigation.32 For example, to investigate whether a 
urodynamic study, which is relatively expensive and might give complications in the patient, 
adds extra predictive value for the prognosis. 
Prediction models in urology
The Rotterdam Prostate Cancer Risk Calculator36, developed on the basis of data derived 
from the European Randomized Study of Screening for Prostate Cancer (ERSPC)37, is a 
successful multivariate prediction model that serves as an example for the development and 
implementation of our prediction model in PFDs. It has been found a useful tool in predicting 
the prostate cancer risk and in avoiding unnecessary testing.36, 38 It is an internet-based 
model which is also available as an app. Its availability for patients, general practitioners and 
physicians and for use at different time points makes it a very usable tool. 
Prediction models are relatively new in managing PFDs and represent a new way of looking 
at PFDs. For example, a recently published multivariate prediction model in PFDs predicts 
the risk of occurrence of UI, fecal incontinence and pelvic organ prolapse in women 12 and 
20 years after childbirth.39 Another recently published model predicts bladder outcomes 
one year after traumatic SCI.40 Both models showed adequate predictive accuracy and 
were externally validated. The clinical impact of implementation of the models is not 
(yet) described. Additionally, some models in the field of PFDs on treatment outcome are 
available. Darekar et al.41 developed a model that predicts the outcome of fesoterodine 
treatment in the management of UUI. Other models predict cystocele recurrence after 
surgical treatment42 or adverse events and continued UI after sling surgery.43 Note that these 
models predict the outcome of one specific treatment. 
The Rotterdam Pelvic Floor Outcome Calculator - PREFOCUS®
In parts I and II of this thesis, the foundations are laid for a prediction model in PFDs in the 
future, that is by evaluating treatment outcomes (chapters 5 and 6) and potential predictors 
(chapter 6), making the first step to standardization of outcomes (chapter 2) and making 
(patient reported) outcome measures available (chapters 3 and 4). In part III, chapter 7, it 
is shown that we are able to develop a multivariate model in the group of PFD patients that 
predicts outcome of UUI treatment. This could be seen as the first part of the construction 
of a complete prediction model in PFDs. The fundamental research questions of this thesis 
are hereby answered. 
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Our future objective is to develop the Rotterdam Pelvic Floor Outcome Calculator, the 
PREFOCUS®, a complete diagnostic, prognostic disease risk and prognostic treatment 
outcome prediction model in PFDs. The focus of the PREFOCUS® will be on the treatment 
outcome part. This part will include all available therapies per specific PFD and will give 
a complete outcome prediction for all therapies. After the development of the total 
PREFOCUS® and its implementation into clinical care, it can aid (shared) decision making 
and also optimize individualized care. The Rotterdam Prostate Cancer Risk Calculator36 and 
other described published prediction models in PFDs may serve as examples for the design 
and implementation into clinical care in the future. 
FUTURE PERSPECTIVES 
A great heterogeneity in outcome reporting in SUI in NU patients was found in our systematic 
review described in this thesis. We hope that findings from this study will start the dialogue 
on this topic and will eventually lead to consensus on what outcome parameter or set of 
outcome parameters to use in the future in this specific patient group. 
We pursue widespread availability and implementation of PROMs in health care and 
specifically for the use in patients with PFDs in the Netherlands. The next steps of our 
research group will be the translation and validation of PROMs for neurogenic PFD patients, 
e.g. the MSISQ-1518, which was identified as best quality PROM for evaluating sexuality 
in neurogenic patients19, and the neurogenic bowel dysfunction score.17 In this research 
field, further improvement in the ease of interpretation of PROMs can be accomplished by 
determining the minimally important change in available Dutch validated PROMs, e.g. for 
the SF-Qualiveen. 
Especially for the ProACT, as a new minimally invasive therapy, further research on long-
term outcomes and identification of the perfect patient group to treat, would add valuable 
information to treatment decision making. Furthermore, outcomes on the quality of life after 
both ProACT placement and AVS construction (in both pediatric and adult patients) would 
add valuable information to existing literature. The identification and further evaluation 
of available therapies in PFDs in combination with identifying outcome predictors could 
eventually lead to a reliable prediction model. 
Our research group will continue this research line, and extension of the PREFOCUS® is 
foreseen. Extension for use in other types of UI and other PFDs, for use by patients, and 
first, second and third line of health care practitioners is intended. External validation44 and 
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impact studies33 should be performed before implementation of the model into practice. 
Furthermore, more predictors will be searched for to improve the model’s predictive value 
and PROMs might be used in the model as an outcome parameter or as a predictor. In 
addition, separate models for the use in different patient groups, such as children and NU 
patients will be created. Developing an internet-based model with availability of an app is 
aimed for. These plans could be realized after initiation of a large prospective multicentre 
study in patients with PFDs. The value of the model will drastically increase after extension. 
After the development of the complete PREFOCUS® and the implementation into clinical 
care, it can be used as an aid in (shared) decision making, managing patients’ expectations 
and it can promote individualized care. 
EPILOGUE
In this thesis, our fundamental research questions on the feasibility of constructing 
prediction models in PFDs have been answered and we can conclude that the foundations 
are laid to develop a complete prediction model in PFDs, the Rotterdam Pelvic Floor 
Calculator - the PREFOCUS®, in the future. As a first step, a multivariate model that predicts 
UUI treatment outcome was developed. An objective multivariate prediction model such as 
the PREFOCUS® has the potential to be used as an aid in decision making in treatment of 
PFD patients in the future and to promote individualized care. It could mean an important 
health care improvement in the future, as the PFD patient population is large45, decision 
making in PFD is complex, and PFDs have major influence on the quality of life.5
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SUMMARY
Pelvic floor disorders (PFDs) such as urinary incontinence (UI) are highly prevalent and have 
great negative impact on the quality of life of a patient. Chapter 1, the general introduction 
of this thesis, introduces the background of PFDs, the use of different outcome measures 
in PFDs and prediction models. Due to various new treatment options in the management 
of PFDs, treatment decision making becomes more important. Objective multivariable 
prediction models can be useful in (shared) decision making and optimization of personalized 
care. A prognostic treatment outcome model can help to identify patients who will and 
will not respond to a certain PFD therapy beforehand. The aim of this thesis is to lay the 
foundations for the development of a complete diagnostic and prognostic prediction model 
in PFDs with the goal of optimizing individualized care. 
The first part of this thesis is about outcome measures: the use of different outcome 
parameters and definitions of cure is studied (chapter 2) and the translation and validation 
of a patient-reported outcome measure (PROM) for the use in the Netherlands is described 
(chapter 3 and 4). 
A systematic review was described in chapter 2. All used outcome parameters and definitions 
of cure used to describe outcome of surgical treatments for stress urinary incontinence 
in neuro-urological (NU) patients were summarized. A great heterogeneity in outcome 
reporting was found. Sixteen different outcome parameters and nine different definitions 
of cure were used in seventeen included studies. This heterogeneity in outcome reporting 
makes it difficult to validly compare outcomes of studies or interventions. We hope that the 
results of this study will begin the dialogue on this issue and will finally lead to a consensus 
on which outcome parameters and definitions of cure to use in this specific patient group 
in the future.
Especially for the NU patient group, there is a lack of validated questionnaires for the use 
in the Netherlands. In chapter 3 and 4 the translation and the validation of the Dutch SF-
Qualiveen, a urinary-specific quality of life PROM for NU patients, is described in multiple 
sclerosis patients (chapter 3) and spinal cord injury patients (chapter 4). Guidelines for 
translation and validation of questionnaires were adhered to. In the test-phase of the Dutch 
SF-Qualiveen, we found good content validity. Good construct validity was showed by the 
predefined hypotheses that were met: SF-Qualiveen scores in patients were higher than 
in controls and patients with higher SF-Qualiveen scores had a higher burden of urinary 
symptoms. A significant correlation was found between the Dutch SF-Qualiveen scores and 
the reference standard (UDI-6) scores, confirming good criterion validity. The intraclass 
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correlation coefficient for agreement of the repeated SF-Qualiveen measurements (baseline 
and 1-2 week later) represents good reproducibility. Internal consistency was confirmed by 
finding that the different items of the SF-Qualiveen were intercorrelated. Unexpectedly, we 
found that the domains of the Qualiveen (the long version of the SF-Qualiveen) were not 
present in the SF-Qualiveen. Therefore, we recommend to only use the total SF-Qualiveen 
and not the separate domains. These validation studies confirm that the Dutch SF-Qualiveen 
can be reliably and validly used in both multiple sclerosis and spinal cord injury patients in 
the Netherlands. 
In part II of this thesis, the outcomes of different interventional therapies to regain urinary 
continence are described. 
In chapter 5, the hypothesis that the relatively new minimally invasive therapy ProACT, 
Prostate Adjustable Continence Therapy, induces changes of the static urethral pressure 
is researched. Patients who were included in this study suffered from UI after radical 
prostatectomy and underwent urethral pressure profilometries before and after ProACT 
placement. It was found that the maximum urethral closure pressure (MUCP) significantly 
increased in the group with successful clinical outcome (the use of no or one precautionary 
incontinence pad per day). In the group with non-successful clinical outcome, no significant 
increase in MUCP was found. When comparing the increase in MUCP between the group 
with successful and non-successful clinical outcome, a statistically significant difference 
was found. In conclusion, successful treatment with ProACT is associated with a significant 
increase of the urethral pressure. This implies that increased urethral pressure contributes 
to the mechanism of action of the ProACT. 
Chapter 6 describes the use, complications, and re-interventions after appendicovesicostomy 
(AVS) placement in children. Indications for placement of an AVS were irreversible lower 
urinary tract dysfunction due to neurological or non-neurological disorders and the inability 
to perform clean intermittent catheterization through the urethra. After AVS construction, 
32% of the patients needed a re-intervention during a mean follow-up of 10 years. The 
most common complications were cutaneous/fascial stenosis, stenosis at conduit-bladder 
level and stomal incontinence. Roughly two thirds of the re-interventions were performed 
superficially and/or endoscopically and the peak incidence of re-interventions was in the 
first year after conduit construction. No variables were identified that could predict the need 
for re-intervention. After the mean follow-up of 10 years, 99% of the patients continued to 
use their conduit for clean intermittent catheterization. 
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In part III, chapter 7, of this thesis, the development of a multivariable model that predicts 
the short-term outcome of urge urinary incontinence treatment in women based on 
patient characteristics, patient history and investigations, is described. The model includes 
six predictors; number of UI episodes/24h, voiding frequency during the day, subjective 
quantity of UI, coexistence of stress urinary incontinence, UI during the night, and bladder 
capacity. The model has a moderate predictive power and some limitations, but it has the 
potential to be used in practice in the future after external validation. The development of 
this model can be seen as the first step in the development of a complete diagnostic and 
prognostic prediction model in PFDs.
In the general discussion, chapter 8, the need for standardization of outcomes, the use of 
PROMs and traditional outcome measures, the development and use of prediction models 
and finally our future perspectives are discussed. By evaluating treatment outcomes and 
potential predictors, making the first step to standardization of outcomes and making 
PROMs available, all chapters of this thesis contribute to the development of a complete 
diagnostic and prognostic (treatment) outcome prediction model in PFDs in the future, the 
Rotterdam Pelvic Floor Outcome Calculator – the PREFOCUS®. It is shown that we are able 
to develop a first model in this patient group to predict the outcome of treatment of PFDs. 
The PRECOCUS® has the potential to be used as an aid in decision making for PFD patients 
in the future and to promote individualized care.
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SAMENVATTING
Bekkenbodemproblemen (BBP) zoals urine-incontinentie (UI) hebben een hoge prevalentie 
en kunnen een grote negatieve invloed hebben op de kwaliteit van leven van een patiënt. 
Hoofdstuk 1, de introductie van dit proefschrift, introduceert het onderwerp van BBP, 
het gebruik van uitkomstmaten bij BBP en het gebruik van voorspelmodellen. Nu er 
verschillende nieuwe behandelingsmogelijkheden zijn ontwikkeld voor BBP, wordt de keuze 
van een behandeling belangrijker. Objectieve multivariabele voorspelmodellen kunnen 
gebruikt worden als hulpmiddel bij (gezamenlijke) besluitvorming en kunnen bijdragen aan 
optimalisatie van gepersonaliseerde zorg. Een prognostisch model om de uitkomst van een 
behandeling te voorspellen, kan gebruikt worden om voorafgaand aan een behandeling 
te identificeren welke patiënten wel en niet baat zullen hebben bij therapie. Het doel 
van dit proefschrift is om de fundering te leggen voor de ontwikkeling van een compleet 
diagnostisch en prognostisch voorspelmodel voor BBP dat de geïndividualiseerde zorg kan 
optimaliseren. 
Het eerste deel van dit proefschrift gaat over uitkomstmaten: het gebruik van verschillende 
uitkomstparameters en definities van genezing wordt onderzocht (hoofdstuk 2) en de 
vertaling en validatie van een patiënt-gerapporteerde uitkomstmaat (PROM) wordt 
beschreven voor gebruik in Nederland (hoofdstuk 3 en 4). 
Een systematische review wordt beschreven in hoofdstuk 2. Alle gebruikte 
uitkomstparameters en definities van genezing die gebruikt werden om de uitkomst van 
chirurgische behandeling van stress urine-incontinentie bij neuro-urologische (NU) patiënten 
te beschrijven, worden opgesomd. Een grote heterogeniteit in uitkomstrapportage werd 
gevonden. Zestien verschillende uitkomstparameters en negen verschillende definities 
van genezing werden gebruikt in zeventien geïncludeerde studies. Deze heterogeniteit 
in uitkomstrapportage maakt het moeilijk om betrouwbaar de uitkomsten van studies 
of interventies met elkaar te vergelijken. Wij hopen dat de resultaten van deze studie 
de discussie over dit onderwerp op gang zal brengen en dat dit uiteindelijk zal leiden tot 
een consensus over welke uitkomstparameters of definities van genezing in de toekomst 
gebruikt dienen te worden in deze specifieke patiëntengroep. 
Er is een tekort aan gevalideerde vragenlijsten voor gebruik in Nederland, in het bijzonder 
voor NU patiënten. In hoofdstuk 3 en 4 wordt de vertaling en validatie van de Nederlandse 
SF-Qualiveen, een blaas-specifieke kwaliteit van leven PROM voor NU patiënten, beschreven 
voor multiple sclerosis (hoofdstuk 3) en dwarslaesie patiënten (hoofdstuk 4). De richtlijnen 
voor vertaling en validatie van vragenlijsten werden gevolgd. In de testfase van de Nederlandse 
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SF-Qualiveen, vonden wij goede ‘content’ validiteit. Goede ‘construct’ validiteit werd 
getoond doordat vooraf gedefinieerde hypotheses werden bevestigd: SF-Qualiveen scores 
waren hoger bij patiënten dan bij controle personen en patiënten met hogere SF-Qualiveen 
scores gaven aan meer hinder te ervaren van hun blaasklachten. Een significante correlatie 
tussen de SF-Qualiveen scores en de referentiemaat (UDI-6) bevestigde een goede ‘criterion’ 
validiteit. We vonden een overeenkomst tussen eerste meting van de SF-Qualiveen scores 
(test) en scores 1-2 weken later (re-test), wat een goede reproduceerbaarheid aantoont. 
Interne consistentie werd bevestigd doordat de verschillende items van de SF-Qualiveen 
met elkaar in verband stonden. Onverwachts vonden wij dat de domeinen van de Qualiveen 
(de lange versie van de SF-Qualiveen) niet konden worden aangetoond in de Nederlandse 
SF-Qualiveen. Daarom adviseren wij alleen de gehele SF-Qualiveen te gebruiken en niet 
de aparte domeinen. De validatiestudies bevestigen dat de Nederlandse SF-Qualiveen 
betrouwbaar en valide gebruik kan worden in multiple sclerosis en dwarslaesie patiënten 
in Nederland. 
In deel II van dit proefschrift, worden de uitkomsten van verschillende invasieve continentie 
behandelingen beschreven.
In hoofdstuk 5 wordt onderzocht of de relatief nieuwe minimaal invasieve therapie ProACT, 
Prostaat Aanpasbare Continentie Therapie, veranderingen in de statische urethrale druk 
veroorzaakt. Geïncludeerde patiënten hadden klachten van UI na radicale prostatectomie 
en ondergingen urethrale druk profilometrie voor en na ProACT plaatsing. De maximale 
urethrale sluitingsdruk (MUCP) was significant verhoogd na ProACT plaatsing in de groep 
met een succesvolle klinische uitkomst: het gebruik van geen of één incontinentie pad 
per dag uit voorzorg. In de groep met een onsuccesvolle klinische uitkomst werd geen 
significante verhoging van de MUCP gevonden na ProACT plaatsing. Wanneer de verhoging 
in MUCP tussen de groepen met een succesvolle en een onsuccesvolle klinische uitkomst 
werd vergeleken, werd een statistisch significant verschil gevonden. Concluderend is een 
succesvolle behandeling met ProACT geassocieerd met een significante verhoging van 
de urethrale druk. Dit impliceert dat verhoging van de urethrale druk bijdraagt aan het 
werkingsmechanisme van de ProACT. 
Hoofdstuk 6 beschrijft het gebruik, de complicaties en de re-interventies na 
appendicovesicostomie (AVS) plaatsing bij kinderen. Indicatie voor plaatsing van een AVS was 
irreversibele lage urineweg dysfunctie met neurologisch of niet-neurologisch onderliggend 
lijden en onvermogen om intermitterende katheterisatie via de urethra te verrichten. Na AVS 
constructie had 32% van de patiënten een re-interventie nodig gedurende een gemiddelde 
follow-up van 10 jaar. De meest voorkomende complicaties waren cutane/fasciale stenose, 
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stenose op de overgang conduit-blaas en stoma-incontinentie. Ongeveer twee-derde van 
de re-interventies werd oppervlakkig en/of endoscopisch uitgevoerd en de piekincidentie 
van re-interventies was in het eerste jaar na conduit-constructie. Er konden geen variabelen 
worden geïdentificeerd die de noodzaak voor een re-interventie konden voorspellen. Na 
een gemiddelde follow-up van 10 jaar gebruikte 99% van de patiënten de conduit nog voor 
het verrichten van intermitterende katheterisatie. 
In deel III, hoofdstuk 7, van dit proefschrift wordt de ontwikkeling beschreven van 
een multivariabel model dat de korte-termijn uitkomst van urge urine-incontinentie 
behandelingen bij vrouwen voorspelt op basis van patiëntkarakteristieken, anamnese en 
aanvullend onderzoek. Het model bestaat uit zes predictoren; aantal UI episoden/24h, 
mictiefrequentie gedurende de dag, co-existentie van stress urine incontinentie, UI 
gedurende de nacht, subjectieve hoeveelheid UI, en blaascapaciteit. Het model heeft een 
matig voorspellende waarde en een aantal limitaties, maar het toont grote potentie gebruikt 
te worden in de praktijk in de toekomst na externe validatie. De ontwikkeling van dit model 
kan gezien worden als de eerste stap in de ontwikkeling van een compleet diagnostisch en 
prognostisch voorspelmodel bij BBP. 
In de algemene discussie, hoofdstuk 8, worden de noodzaak voor standaardisatie van 
uitkomsten, het gebruik van PROMs en traditionele uitkomstmaten, de ontwikkeling 
en het gebruik van predictiemodellen en uiteindelijk onze toekomstige perspectieven 
bediscussieerd. Door (de uitkomsten van) behandelingen en potentiële predictoren te 
evalueren, door de eerste stap richting standaardisatie van uitkomsten te zetten en door 
PROMs beschikbaar te maken, dragen alle hoofdstukken van dit proefschrift bij aan de 
ontwikkeling van een compleet diagnostisch en prognostisch (behandelings-) uitkomst 
predictiemodel voor BBP in de toekomst, de Rotterdam bekkenbodem uitkomst calculator, 
de PREFOCUS®. Er is aangetoond dat wij in staat zijn een eerste model te ontwikkelen dat 
de uitkomst van behandeling bij BBP voorspelt. De PREFOCUS® kan in de toekomst gebruikt 
worden als een hulpmiddel bij het maken van keuzes in de behandeling van BBP patiënten 
en voor het optimaliseren van geïndividualiseerde zorg. 
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A
DANKWOORD
Wie had vóór 2015 gedacht dat dit moment, de dag dat ik ga promoveren, ooit zou komen? 
Ik zelf denk ik nog het allerminst! Maar wat heb ik veel geleerd en wat is dit waardevol voor 
mijn toekomst. Graag wil ik de mensen die mij hier op welke manier dan ook bij hebben 
geholpen even in het zonnetje zetten: 
Om te beginnen de studiepatiënten die mee hebben gewerkt aan mijn onderzoeken. Zonder 
de medewerking van deze patiënten, had mijn proefschrift er nooit kunnen komen, bedankt! 
Jeroen en Bertil, jullie zijn samen een bijzonder co-promotoren duo. Jeroen, je was er 
voor zowel overleg over onderzoek, als ook voor een kletspraatje over de vakantie of het 
weekend. Je laagdrempeligheid was fijn samenwerken. Bertil, nadat we samen gesprekken 
hadden voor het opzetten van samenwerking met andere ziekenhuizen, begonnen we 
elkaar te begrijpen. Sindsdien werkten we echt samen en konden we samen goed sparren 
over ideeën voor toekomstig onderzoek. Bedankt voor jullie hulp bij mijn promotie! 
Prof. Bangma, zonder promotor kun je natuurlijk niet promoveren, bedankt daarvoor. 
Graag wil ik alle leden van de kleine commissie en de grote commissie van harte bedanken 
voor hun interesse in mijn proefschrift. 
Collega’s van de functionele urologie: Jan (Groen), bedankt voor al jouw hulp! Je hebt me 
bij het onderzoek met de ProACT op weg geholpen en geholpen bij het schrijven van mijn 
eerste artikel. We hebben in veel projecten fijn samengewerkt. Erik, bedankt voor je hulp bij 
inclusies van patiënten. Elaine en Lisette, dank voor het opzetten van de onderzoekslijn van 
de functionele urologie waarop ik weer verder kon bouwen. 
Toscane en Ilse, bedankt voor jullie hulp bij de onderzoeken uit dit boekje. Toscane, vooral 
de leuke tijd samen op congres in Florence zal ik onthouden. Ilse, je zorgde voor wat extra 
drukte en energie in de werktuin, heel gezellig! Veel succes allebei, samen met Tess, met het 
voortzetten van de onderzoekslijn. 
Het begon voor mij in Rotterdam bij de kinderurologie, bedankt kinderurologen voor jullie 
ondersteuning zowel op klinisch als op wetenschappelijk vlak. Nancy en Brigitte, jullie 
hebben me zo goed geholpen zowel eerst in de kliniek als met de praktische dingen rondom 
mijn onderzoek. Dankjulliewel! 
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‘Leden’ van de lunchgroep, bedankt allemaal voor de gezelligheid, voornamelijk tijdens 
lunches in het Na gebouw op de 17e verdieping. 
Monique, je hebt me een hart onder de riem gestoken op een moment dat ik het nodig had, 
dat heb ik heel erg gewaardeerd. Verder hoop ik van harte, na alle energie die wij er samen 
met veel anderen in hebben gestoken, dat het predictiemodel in de toekomst uitgroeit tot 
iets moois. 
Urologen en medewerkers van de polikliniek urologie uit het Amphia ziekenhuis en 
Havenziekenhuis, en de polikliniek revalidatiegeneeskunde in Rijndam allemaal hartelijk 
dank voor jullie hulp bij het opzetten van de multicenter onderzoeken uit dit proefschrift. 
In het bijzonder wil ik hiervoor Josien Wolterbeek, Deric van der Schoot en Tebbe Sluis 
bedanken! 
Alle andere co-auteurs: Ida, Jan (van Beek), Daan, Joop, Katja, en Telma bedankt voor jullie 
werk en adviezen om uiteindelijk samen de beste artikelen te maken! 
Ko, wat fijn dat je mij wegwijs hebt gemaakt in het ‘biomedisch Engels schrijven’ en dat je 
na deze cursus altijd bereid was om een kritische blik te werpen op de Engelse formulering 
van mijn stukken. Je was en bent zo betrokken, dat is bijzonder. Je hebt me enorm geholpen, 
hartelijk dank! 
Verena, bedankt voor je hulp rondom alle praktische dingen van de onderzoeken, zoals 
aanvragen voor de METC. 
Ik werd begin januari 2018 door alle artsen (Nicole, Anna, Wilma, Hadewych, en Friso), 
doktersassistenten (Marianne, Atie, Karin, en Astrid) en medewerkers van de zorg bij de 
Buitenhof met open armen ontvangen. Bedankt voor jullie interesse in de laatste fase van 
mijn promotie en jullie medewerking en geduld bij het inplannen van de promotiedatum. 
Stephanie, wat leuk dat we samen aan het promoveren waren in het Erasmus: jij bij de 
KNO en ik bij de urologie! Gezellig konden we tussendoor even koffie drinken of lunchen 
en spreken over alle dingen rondom het promoveren. Jammer genoeg is deze tijd nu wel 
voorbij…
Liesbeth, we zijn vrienden geworden tijdens onze co-schappen in Deventer. We kunnen 
goed met elkaar praten over de geneeskunde, maar ook wel over de relativiteit van het vak 
en de ziekenhuiswereld. Dat heeft mij geholpen bij het inslaan van een nieuwe weg in mijn 
carrière, dankjewel! Fijn dat je mijn paranimf bent! 
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A
Linde, wat was je verbaasd toen ik vertelde dat ik ging promoveren, maar je twijfelde geen 
moment of ik dit wel kon. We wonen best ver uit elkaar en spreken elkaar tegenwoordig niet 
meer zo regelmatig, maar onze vriendschap blijft!
Anne Laurine, wat heb je je boos gemaakt voor mij! Op de belangrijke momenten in mijn 
leven ben je aanwezig, ik kan op je terugvallen en hopelijk blijft dit altijd zo. We delen heel 
veel, je hebt zelfs die kleine van jou mijn naam meegegeven voor de rest van haar leven, 
heel erg bijzonder! 
Anne en Sophia, toch wel bijna wekelijks de laatste tijd hoorden jullie over alle ophef rondom 
de promotie en urologie. Dank voor het aanhoren van dit alles, jullie steun was heel fijn. We 
kunnen met elkaar delen wat bijzonder is, wat leuk is, wat mooi is en ook wat verdrietig is 
en jullie zijn daarom dierbaar voor mij! 
Mam, je bent er altijd voor me. Je wilde precies op de hoogte zijn van alles rondom artikelen, 
publicaties en de promotie maar zag soms door de bomen het bos niet meer. Als antwoord 
op de vraag die jij me laatst stelde: het is goed als je alleen de samenvatting van dit boekje 
leest ;) Floris, Margot, Derk, Justus, Hildy, Raymonde, René, Milou en Timo, bedankt voor 
jullie interesse en meeleven met alles rondom mijn promotie en urologie de afgelopen tijd, 
fijn dat jullie er waren. 
En alle andere lieve vrienden en familie die interesse hebben gehad in mijn verhalen over 
promotie en de urologie, die altijd achter mij staan en die ook voor de nodige ontspanning 
hebben gezorgd in de tijd van mijn promotie. Bedankt!
En dan mijn lief, Marijn, je hebt veel van mij aan moeten horen, want promoties gaan niet 
altijd (of misschien altijd niet?) soepel. Jij hebt mij in een moeilijke tijd onvoorwaardelijk 
gesteund, je hebt me geholpen en je was er altijd. Omdat jij altijd aan mijn zij staat, wil ik je 
ook graag aan mijn zij op 23 mei als mijn paranimf! Ik ga samen met jou positief de toekomst 
tegemoet. 
De wereld ligt aan onze voeten! 
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Name PhD student: Sarah Reuvers
Erasmus MC Department: Urology
PhD period: 
January 2015 – May 2018
Promotor(s): 
prof. dr. C.H. Bangma 
Supervisor: dr. J.R. Scheepe, 
dr. B.F.M. Blok
1. PhD training
Year Workload
(Hours/ECTS)
General courses 
- Research Integrity, January 2015
- Biomedical English Writing Course, March – May 2015
- BROK ‘Basiscursus Regelgeving Klinisch Onderzoek’, e-learning 
course, September 2015
- Basic Introduction Course on SPSS, November 2015
- Course on NCBI, Pubmed, April 2016
- Survival Analysis course, June 2016
- Microsoft Excel 2010 course, April 2017
- ZorgSamenEvent, April 2017
- VVAA Workshop ‘Loopbaanontwikkeling’, May 2017
2015
2015
2015
2015
2016
2016
2017
2017
2017
0.3 ECTS
2.0 ECTS
1.5 ECTS
1.0 ECTS
0.7 ECTS
1.0 ECTS
0.3 ECTS
0.3 ECTS
0.2 ECTS
Specific courses (e.g. Research school, Medical Training)
- Systematic Review Course, Amsterdam, EAU guidelines office, 
February 2015
2015 1.0 ECTS
Seminars and workshops
- Department Journal Club
- Department educational program ‘Onderwijsuur’
- Department educational program ‘Refereeravonden’ 
2015 - 2017
2015 - 2017
2015 - 2017 
3.0 ECTS
1.0 ECTS
1.0 ECTS
Presentations
- Oral presentation ‘UPPs after ProACT’, NVU, November 2015 
- Presentation ‘New studies in neuro-urology’, dept of Urology 
education Erasmus MC, February 2016
- Oral presentation ’20 years appendicovesicostomy’, educational 
programme (Refereeravond) Erasmus MC, March 2016
- Oral presentation ‘Validation of the Dutch SF-Qualiveen’ NVU, 
May 2017
- Oral presentation ‘alphablockers in female patients with MS’, 
NVU, May 2017 
- Poster presentation ‘Validation of the Dutch SF-Qualiveen’, ICS, 
September 2017
- Poster presentation ‘Heterogeneity in reporting on outcome’, 
ICS, September 2017 
2015
2016
2016
2017
2017
2017
2017
1.0 ECTS
0.3 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
1.0 ECTS
(Inter)national conferences
- NVU Nieuwegein, November 2015
- EAU Munich, March 2016
- NVU, May 2016
- EAU London, March 2017
- NVU, May 2017
- ICS Florence, September 2017
2015
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2016
2017
2017
2017
1.0 ECTS
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1.5 ECTS
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Other
- Associate member of Neuro-Urology EAU guidelines panel 2016 - 2017 2.0 ECTS
2. Teaching
Year Workload 
(Hours/ECTS)
- Coaching bachelor students
- Course on coaching bachelor students, February 2016
- Intervision on coaching, May 2016
2015 – 2017 
2016
2016
1.5 ECTS
0.2 ECTS
0.2 ECTS
Supervising interns
- During clinical hours at the paediatric urology department 2015 1.0 ECTS
Total                   31.0 ECTS
UITNODIGING
Voor het bijwonen van de openbare 
verdediging van het proefschrift
Outcomes in 
Functional Urology: 
Towards a prediction model 
in pelvic floor disorders
Door Sarah Reuvers
Op woensdag 23 mei 2018 
om 13.30 uur
Erasmus MC Onderwijscentrum, Eg-370
Prof. Andries Queridozaal
Wytemaweg 80
3015 CN Rotterdam
Aansluitend zal er een borrel 
zijn in Het Nieuwe Café 
(Museumpark 25, Rotterdam, op 
loopafstand van het Onderwijscentrum) 
U bent hier van harte welkom! Wilt u 
voor 9 mei doorgeven of u komt?
Paranimfen:
Marijn Verhoef
Liesbeth Altink
sarah.promotie@gmail.com
Cadeautip:  
Voor het uitzoeken van een mooi 
aandenken aan deze dag.
Outcomes in Functional Urology:
Towards a prediction model in pelvic floor disorders
Sarah Reuvers
O
utcom
es in Functi
onal U
rology: Tow
ards a predicti
on m
odel in pelvic floor disorders 
Sarah Reuvers
